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1 General introduction
In the countries of north-western Europe,
lung cancer is the most common cancer in
males [1-3]. In the Netherlands, almost
8500 persons died of lung cancer in 1987
(about 7500 men and 1000 women) and
another 261 had lung cancer as secondary
cause of death, according to the
Netherlands Central Bureau for Statistics
[4]. Annually, lung cancer will be diagno-
sed presumably in about 9500 patients
(8200 men and 1300 women) [4], in other
words, 1 out of every 11 men will develop
lung cancer before the age of 75 versus 1
out of every 60 women [5, 6]. The world
standardised incidence rates were 81.3 for
men and 10.1 / 100000 for women, for the
two most southern areas of the Dutch
provence of Limburg [7].
Since 1985 the high lung cancer incidence
among males has gradually declined, whe-
reas the low incidence for females rapidly
increased since 1989 [5]. At the same
time, the age-adjusted incidence and the
proportional distribution of histologieal
types showed a striking increase in adeno-
carcinoma for males, while a decline was
observed in squamous and small cell carci-
noma [4|. For females the incidence of all
types, including undifferentiated cancer,
increased [4]. Small cell lung cancer
(SCLC) accounted for 17% of all lung
cancer in males and 23% in females [4, 6].
The changes in lung cancer rates and dis-
tribution of histologieal types are probably
related to changes in smoking behavior, as
the number of male smokers declined and
female smokers sharply rose [5, 6].
Small cell lung cancer distinguishes itself
from other types of lung carcinomas by a
remarkable propensity for early systemic
spread and substantially greater initial
sensitivity to chemotherapy and radiothe-
rapy [8-13]. Nearly all patients have
mediastinal or systemic metastases at the
time of initial diagnosis, precluding thera-
py with surgery alone [14-16].
Combination chemotherapy will result in
objective response rates in 85 to 95% for
limited disease and in 65 to 85% in
extensive disease patients [17]. Complete
responses can be produced in about 50%
of limited disease and in about 25% of
extensive disease patients [17].
Depending on the addition of radiothera-
py, in limited disease patients about a
third will have disease free survival in
excess of two years. Long term disease
free survival in extensive disease patients
is unusual. Despite constant refinements
and changes of the therapy, long term sur-
vival remained stable at a 10 to 20% at
two years [18, 19] and a poor 5% at five
years [20], in the last decade.
A wide array of neurologic complications,
diverging from brain metastases to para-
neoplastic disorders, can complicate
SCLC [21-24]. Neurologic complications
of SCLC are mainly metastatic in nature;
about 10% of the patients have brain
metastases at initial diagnosis, about 30%
subsequently develop brain metastases
during treatment, and at autopsy the fre-
quency is approximately 50% [25-27].
The actuarial risk of brain metastases
increased with lengthening of survival to
10
50 to 80%, at two years from diagnosis
[28-30]. Though the use of prophylactic
cranial irradiation (PCI) effectively redu-
ced the frequency of brain metastases
[31-33], PCI became controversial as it
did not provide any survival benefit and
was associated with central nervous sys-
tem (CNS) toxicity [34-35].
Manifestations of neurotoxicity and para-
neoplastic syndromes may be confused
with symptomatic CNS metastases. The
pathogenesis of PCI related neurotoxicity
is insufficiently understood as it is predo-
minately described in small series of long
term survivors, treated and analysed diffe-
rently [36-50].
In this thesis, several aspects of brain
metastasis in SCLC are investigated. The
data used for most studies were yielded
by a SCLC case register program, which
began in October 1980. As part of this
program patients with SCLC were seen
by a neurologist at diagnosis and regular
intervals thereafter. A CT-scan of the
brain, MR-scan after 1991, was routinely
performed at initial staging. More fre-
quent neurologic consultations and other
diagnostic tests were performed if requi-
red. Long term survivors were examined
in different hospital troughout the
Netherlands by a neurologist and ncuro-
psychologist. The goals of the study thesis
were:
• to describe the results of a neurologic
follow-up of 203 consecutive patients
with SCLC (chapter 1);
• to study the value of histopathologic
subtyping of SCLC in predicting neurolo-
gic complications (chapter 2);
• to investigate the value of CT-scan
(chapter 3) and MRI (chapter 4) for the
detection of brain metastases, in context
to the initial staging procedure;
• to describe the efficacy and safety of
PCI in 203 consecutive patients with
SCLC (chapters);
• to prospectively study the cognitive
functioning of 32 consecutive patients
with SCLC (chapter 6);
• to retrospectively investigate the neuro-
logic outcome of 59 long-term survivors of
SCLC (chapter 7).
Neurologic disorders are a frequent and
enthralling problem in patients with
SCLC. Some clinical aspects of brain
metastasis in SCLC and its treatment are
highlighted in this thesis.
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Introduction , • >'t n
Small cell lung cancer (SCLC) comprises
about 25% of all lung cancers [1,2]. In
patients SCLC is very aggressive and
nearly always metastatic at the time of
presentation, precluding therapy with sur-
gery or chest irradiation alone [3]. The
median survival of untreated patients is
about 3 months from diagnosis, whereas
combination chemotherapy, with or wit-
hout radiotherapy, has provided improve-
ments in median survival to almost a year,
and 10% long-term, potentially cured sur-
vivors [4].
Neurologic disorders are a frequent and
for the neurologist a fascinating problem
in patients with SCLC. Central nervous
system (CNS) metastases are diagnosed
more frequently in SCLC than in other
types of lung cancer [5]. Brain metastases
are the most frequent sort of CNS meta-
stases, and are an important cause of mor-
bidity and mortality in patients with
SCLC [f>,7|. The actuarial probability of
developing brain metastases increases
with lengthening of survival to 50-80% at
two years from diagnosis [6-9]. Because of
its neuroendocrine properties, SCLC is
associated with a wide array of paraneo-
plastic syndromes [10-14]. Treatment of
SCLC, the combination of chemotherapy
and cranial irradiation in particular, is
potentially neurotoxic and can contribute
to brain injury as well [14-21].
Neurologic disorders have been studied
retrospectively, and mainly by pulmonolo-
gists and oncologists in previous reports
[5-21 ]. In the present article, the results
of a prospective neurologic follow-up
study are presented. The present study
was undertaken to investigate the clinical
frequency and course of the neurologic
complications of SCLC.
Patients and methods
Patients
From January 1983 to January 1993, 203
consecutive patients with microscopically
proven SCLC were included in this pro-
spective study. Till January 1994 minimal
follow up was 1 year or until death. Initial
staging of these patients by a pulmonolo-
gist, was based on physical examination,
standard blood and chemistry profile,
chest x-ray, CT-scan of the chest, ultra-
sound of the abdomen, radionuclide bone
scan, fibre optic bronchoscopy, and bone
marrow aspirate and biopsy. Limited dise-
ase (LD) was defined as tumor confined
to the ipsilateral hemithorax, the medias-
tinum, and the ipsilateral and/or contrala-
teral scalene and supraclavicular lymph
nodes. In extensive disease (ED) tumor
was found beyond these site.
Treatment
All patients were initially treated with a
combination chemotherapy regimen, con-
sisting of cyclophosphamide 1000 mg/m2,
doxorubricin 45 or 50 mg/m2, and etopos-
ide 100 mg/m2 on day 1,3, and 5 for at
least five cycles. Chemotherapy was
sometimes followed by radiotherapy to
16
Patients
Total 79 129
Men /Women
Median age at diagnosis (range)
Complete remission
Prophylactic cranial irradiation
Disease stage
limited
59/15
64 (39-84) 65
37
17
extensive
111/18
(45-89)
30
5
Table 1. Patient characteristics.
the primary tumor site. Restaging was
performed after five courses of chemothe-
rapy and consisted of physical examina-
tion, and repetition of those examinations
which were abnormal at the initial staging
procedure; complete remission (CR) was
defined as a total resolution of all detecta-
ble lesions.
Only patients who obtained CR were can-
didates for treatment with PCI. Till 1986
LI) and ED patients could opt for PCI,
after 1986 LI) patients only, and in 1990
PCI was excluded from the treatment
protocol. Between 1983 and 1988, two eli-
gible LI) patients refused PCI. Patient
characteristics and treatment specifica-
tions are listed in WVc /. PCI was admi-
nistered to the entire cranial content fol-
lowing completion of chemotherapy.
Patients were treated with a linear accel-
lerator. usually 6 MV photons, using two
lateral opposed fields. The dose was cal-
culated in the mid plane, and delivered in
daily fractions of 3 Gy, 4 times a week, up
to a total dose of 30 Gy. During 1988 and
1990 the radiation technique was chan-
ged, the fraction dose being lowered to
2Gy, 5 fractions per week up to a total
dose of 30 Civ.
Palliative treatment of manifest brain
metastases consisted of daily treatment
with fractions of 3 Gy, 4 times a week, up
to a total dose of 30 Civ. Treatment of
leptomeningeal metastases consisted of
intrathecal methotrexate and systemic
corticosteroid medication, which was
sometimes combined with local radiothe-
rapy at symptomatic sites. Therapy for
spinal metastases comprised radiotherapy
concurrent with corticosteroid medica-
tion. Radiotherapy was initiated a few-
hours after diagnosis was made if signs of
spinal cord compression were present,
otherwise within 48 hours. Dose and
schedule were tailored to site and extent
of metastasis.
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Disorders n % of total
Total ..,,-,.,-
Metastatic
brain metastases
leptomeningeal metastases
spinal metastases
• epidural
• spinal cord
Non Metastatic
peripheral neuropathy
• chemotherapy
• unknown cause
• diabetes mellitus
• alcohol
parancophistic syndromes
• SIADH
• Lambert-Eaton myasthenic syndrome
• subacute cerebellar degeneration
• limbic encephalitis
other
encephalopathy
• possible treatment-related
• metabolic
•steroid myopathy
•radiation plexopathy
•cerebrovascular accident
174
118
79
22
17
14
3
55
23
12
5
4
2
16
11
3
1
1
16
12
8
4
2
1
1
100
67.8
45.4
12.6
9.8
8.0
1.7
31.6
13.2
6.9
2.9
2.3
1.1
9.2
6.3
1.7
0.6
0.6
9,2
6.9
4.6
2.3
1.1
0.6
0.6
Table 2. Neurologic disorders in 203 consecutive patients with small cell lung cancer.
SIADH = syndrome of inappropriate secretion of antidiuretic hormone.
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Neurologic follow-up
Patients were seen by a neurologist at
diagnosis and at quarterly intervals (bi-
annually after a year). Pretreatment a CT-
scan of the brain was performed until
1989, thereafter a MRI. More frequent
neurologic consultations and other auxilia-
ry diagnostic tests took place if required.
In patients with a long-term survival
(defined as 2 years or longer from diagno-
sis) an additional CT-scan of the brain or
MRI was performed. Abnormal brain
functioning found in long-term survivors,
was designated as possible treatment rela-
ted encephalopathy unless otherwise cle-
arly explainable.
Statistics
Overall survival was calculated from
SCLC diagnosis to death or end of obser-
vation period, brain metastatic free survi-
val from SCLC diagnosis to the diagnosis
of brain metastases or end of observation
period. Survival curves were estimated by
the Kaplan-Meier method, differences
tested by the Log-rank test. A p-value of
less than 0.05 was considered to be statis-
tically significant.
Results
A total number of 174 neurologic disor-
ders were diagnosed in 134 patients
(66%); 23 patients had 2 neurologic disor-
ders, and 9 patients had more than 2 dif-
ferent neurologic disorders. The diverse
disorders are listed in /tf/VrZ The majority
of the complications, 161 (93%), were
directlv related to SCLC or its treatment.
Metastatic complications predominated.
Brain metastases were found at initial
diagnosis of SCLC in 27 patients, and
during the course of disease in 52
patients. Histopathologic examination of
the brain metastases after autopsy (n =
12) or neurosurgical intervention (n = 3)
revealed a different diagnosis in 2
patients (another primary tumor n = 1,
non-SCLC relapse after CR of SCLC n =
1). In the remaining patients the diagno-
sis SCLC was confirmed.
Brain metastatic free survival of LD and
ED patients was significantly different (p
< .01, Log-rank test). Two years from
diagnosis, the cumulative risk of brain
metastases reached 47% for LD and 69%
for ED patients, see //£,'///•<" /. The overall
survival of patients with initial brain
metastases did not differ significantly
from the survival of ED patients without
initial brain metastases (p = .12, Ixig-
rank test). Survival following diagnosis of
brain metastasis was significantly longer
for patients with initial brain metastases
than for LD and ED patients with delay-
ed brain metastases (p < .01, Log-rank
test), see //«////'Z The median survival of
12 patients with initial CNS-limitcd dise-
ase was not better than the median survi-
val of other patients with initial brain
metastases, 2.1 months (range, 0.6 to
15.8) versus 5.1 months (range, 0.2 to
25.2). Eight out of 12 patients with initial
CNS-limited disease died early due to
various complications (sepsis n = 5, and
haemorrhage in cerebral metastasis n = 1)
or progressive disease (no response n = 1,
and therapy refused n = 1).
19
proportion brain metastatic free surviving
10 15
Time (months)
Figure 1. Cumulative risk of brain metastases in limited (LD) and extensive disease (ED)
patients.
proportion surviving
10 15
Time (months)
Figure 2. Survival following diagnosis of brain metastases for patients with initial brain metastases
diagnosed prior to therapy (I), and limited (LD) and extensive disease (ED) patients with delay-
ed brain metastases diagnosed during or after therapy.
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Figure 3. Staging MR scan with solitary metastasis in pineal gland (A). The volume of the meta-
stasis remained unchanged for 13 months with chemotherapy alone (B). Secondary tumor growth
and the hydrocephalus (C) were treated with vertriculair drainage and cranial irridation, which yiel-
ded complete radiologic and neurologic remission (D) for the remaining 6 months of the patient's
life.
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The volume of a solitary metastasis in the
pineal gland of a neurologically asympto-
matic patient with a CNS-limited disease
remained the same for 13 months using
only chemotherapy, see figure 3.
Secondary tumor growth and hydrocepha-
lus were treated with ventricular drainage
and cranial irradiation, which obtained
complete radiologic and neurologic remis-
sion till death, 6 months later due to sys-
temic relapse.
Clinical diagnosis of leptomeningcal
metastases was confirmed by liquor cyto-
logy or autopsy in 13 of 22 patients. In
most patients, therapy provided relief of
symptoms for a few months. Median sur-
vival after leptomeningeal metastasis was
1.0 month (range, 0.1 to 11.8). In patients
with back pain or signs of a spinal cord
lesion, ancillary diagnostic tests for spinal
metastases were carried out. The 14
patients with epidural metastases lived a
median of 1.6 months (range, 0.2 to 14.7).
Two patients with back pain only, lived
0.4 and 2.3 months afterwards. Spinal
cord metastasis was found in 3 patients by
MRI. All patients with spinal cord meta-
stases suffered from back pain at diagno-
sis.
The most frequent parancoplastic syndro-
mes was SIADH (syndrome of inapprop-
riate secretion of antidiuretic hormone),
diagnosed in 11 patients (6.3%) w ho pre-
sented with a hyponatremia induced
encephalopathy. at the time of diagnosis
of SCLC or early during the course of the
disease. In most patients SIADH subsi-
ded with chemotherapy of SCLC. Median
survival of patients with SIADH was 6.8
months (range 0.1 to 13.6).
Antibody mediated paraneoplastic neuro-
logic syndromes, were diagnosed in 5
patients (1.7%) only. Lambert-Eaton
myasthenic syndrome was diagnosed in
one patient 6.7 months before diagnosis
of SCLC was made. The clinical manifes-
tations of limbic encephalitis existed in
one patient 3.5 months prior to diagnosis
of SCLC. The course of the antibody
mediated paraneoplastic syndromes was
not influenced by the treatment of
SCLC, and either remained stable or
progressed slowly. Median survival of
patients with antibody mediated paraneo-
plastic syndromes was 4.0 months (range
0.7 to 13.2).
Adverse effects of treatment were noticed I
in 23 patients (13%); peripheral neuropa- i
thy due to chemotherapy was reversible, I
whereas the other treatment-related com-
plications were not. The number of sen-
son.' neuropathies was probably underesti-
mated in the total number of polyneuro-
pathies; during chemotherapy many
patients complained of temporary numb-
ness or tingling sensations over the distal
parts of their extremities, mostly without
further clinical evidence of a polyneuropa-
thy or elcctromyographic abnormalities.
Possible treatment-related encephalopat-
hies were diagnosed in 8 of the 18 long-
term survivors (7 with and 1 without
PCI). Symptoms and signs had an ins-
idious onset within 6 months following
the termination of PCI, and comprised
memory disturbances in 4 patients.
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memory disturbances with temporary
lethargy in 2 patients, and progressive
memory disturbances w ith apathy in 2
patients. Except for the latter 2 patients,
symptoms remained stable. Steroid myo-
pathy was diagnosed in two patients with
brain metastases and a protracted course
of disease.
Discussion
The natural course of SCLC, known of as
rapidly progressive and almost always
fatal, has been protracted by the use of
chemotherapy with or without the use of
radiotherapy. The median survival has
improved to 13-16 months for LD
patients and to 7-10 months for ED
patients [22,23). A minority of patients
with SCLC is cured, 10% of all patients,
and 20% of patients with favourable pro-
gnostic factors [24]. With lengthened sur-
vival some clinical manifestations of
SCLC have become more apparent and so
has the risk of CNS spread.
Approximately 10% (had brain metastases
at diagnosis of SCLC [6,25], a further
20% developed brain metastases during
therapy [6,25], and about 50% had brain
metastases at autopsy [6,8,25]. At 2 years
from diagnosis, the cumulative risk at
brain metastases reached 50-80% for
patients not treated with PCI and in CR
[6-8], and nearly 100% for patients who
did not achieve CR regardless of treat-
ment with PCI [26].
and at 2 years from diagnosis were in
accordance with the data of other snides
[6,8,25]. Autopsy rate was relatively low,
revealing a different histology of brain
metastases in 13% of patients.
Explanations for the differences in histo-
logy may be found in alterations of cell
morphology with therapy or time, and
development of a second primary tumor
[27-29]. Studies investigating the pro-
gnostic implications of histologic subty-
pingof SCLC were inconclusive as yet
[30]. A relationship between histologic
subtypingof SCLC and brain metastases
was not found either, but hope existed
that histologic subtyping could be useful
in deciding whether or not to use PCI
[30,31].
The prognosis of patients with initial pre-
sentation of brain metastases is not neces-
sarily worse. If treated with cranial irradia-
tion when brain metastases appeared,
Hazel et al [32] found no differences in
survival between LI) patients and
patients with the CNS as sole metastatic
site. Because of the high frequency of
intracranial metastases with the use of
chemotherapy, it was assumed that the
CNS was a relative chemotherapy sanctu-
ary enclosed by the blood brain barrier.
Reports of radiologically proven responses
of cerebral metastases to systemic chemo-
therapy [331 encouraged several investiga-
tors to undertake trials with systemic che-
motherapy for brain metastases [34].
In the present study, frequencies of brain Kristensen et al [35] compiled from data
metastases at diagnosis, during treatment, in the literature a cumulative response
23
rate of 75% and complete response rate of
44% for therapeutic cranial irradiation,
and a cumulative cumulative response
rate of 43% and complete response rate of
13% for delayed brain metastases. As the
response of initial brain metastases to
chemotherapy was almost as good as to
cranial irradiation, it seems logical to wait
for the effect of first line chemotherapy.
In patients with delayed brain metastases
who probably developed resistance to
cytotoxic drugs and therefor have a shor-
tened life expectancy, brain metastases
should be treated with irradiation.
Irradiation attains a slightly better respon-
se rate and is less toxic than chemothera-
py [35j.
In the present study, survival of patients
with CNS-limited disease was poor
because 8 of 12 patients (66%) died early
from complications. Treatment of initial
brain metastases generated a significantly
better response than treatment of delayed
brain metastases, in terms of survival. The
better response could be caused by a gre-
ater sensitivity of the tumor or the more
intense treatment given, during the initial
stage of the disease. Only one patient was
treated for brain metastases with chemo-
therapy alone; in this case, a solitary brain
metastasis in the pineal gland remained
clinically silent for a considerable time.
When the pineal gland metastasis finally
became symptomatic, radiotherapy yiel-
ded CR till death, neurologically and
radiologically. Though the pineal gland is
not a good example with its strong vascu-
larisation and its relatively untight blood
brain barrier, this case raises the question
whether initial treatment of brain meta-
stases with chemotherapy should be follo-
wed by consolidation radiotherapy.
Whether or not chemotherapy treated
patients with initial brain metastases
should receive consolidation cranial irra-
diation remains to be seen [35].
In contrast to symptomatic treatment of
brain metastases, PCI may contribute in
curing patients. Rosenstein et al [36]
found PCI effective in increasing survival
of LD patients with durable thoracic con-
trol. The use of PCI is still under discus-
sion; in randomised studies it reduced the
frequency of brain metastases from 25 to
5%, but did not benefit survival and was
associated with an increased riskofCNS
toxicity [37]. In the present study, we
found possible treatment-related impair-
ment in 6 (33%) and disability in 2 (11%)
of the 18 long-term survivors. Of the 8
patients with possible treatment-related
brain injury 7 had received PCI. However,
in individual patients it remains very diffi-
cult to identify retrospectively causal fac-
tors for the rather aspecific features of
possible treatment-related brain injury.
The most common anatomic abnormali-
ties shown by CT scan or MR1 following
PCI treatment are white matter lesions
and general brain atrophy. These abnor-
malities are linked to a wide range of cli-
nical manifestations, and are indistinguis-
hable from normal ageing processes as
leucoaraiosis, by imaging techniques [38].
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Paraneoplastic syndromes can be divided
in hormone mediated and antibody
mediated. Up to 54% of patients may
have elevated hormone levels [39]. •?
However, in the literature, the clinical
frequency of a hormone mediated parane-
oplastic syndromes as SIADH, varies from
9.5% to 12% 110 ]. 1 n the present study,
the frequency was lower as we were focu-
sed on neurologic abnormalities and not
all patients with SIADH have a neurologic
presentation. Antibody mediated neurolo-
gic paraneoplastic syndromes have a fre-
quency of approximately 3% [40], coinci-
ding with our results percentage wise.
Therapy of SCLC was effective for the
hormone mediated, but not for the anti-
body mediated paraneoplastic syndromes.
The longitudinal nature of the present
study yielded a high frequency of neurolo-
gic disorders in SCLC patients, more so
than in previous retrospective reports [5-
21 ]. Brain metastases were the most com-
mon complication. The different con-
cepts regarding the treatment of brain
metastases need further investigation.
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' I The role of histopathologic
subtyping in predicting neu-
rologic complications in
small cell lung cancer
29
Introduction
Many early studies have focused on the
clinical implications of histologic subty-
ping of small cell lung cancer (SCLC) fi-
ll ]. A few studies reported differences in
metastatic CNS patterns for particular
SCLC subtypes [1-3] and one of the aut-
hors [1 ] suggested that histologic subty-
ping could be useful in deciding whether
or not to use prophylactic cranial irradia-
tion (PCI). In SCLC cell lines, the classic-
small and variant subtypes show obvious
differences in morphology, expression of
ncuroendocrine markers and oncogenes,
and resistance to chemotherapy and radio-
therapy |12-14]. However, initial studies
investigating histologic subtyping of
SCLC revealed conflicting data with
respect to prognosis [ 1-8]. This was attri-
buted to a lack of reproducible criteria,
which is why the pathology panel of the
International Association for the Study of
Lung Cancer (IASLC) developed a new
subdassification [15,16]. This classifica-
tion system was correlated to cell culture
work and recognizes three subtypes:
small, mixed, and combined [15,16] and
offers the best interobserver reproducibi-
lity thus tar [9,10.16].
Relationships between this classification
system and neurologic complications have
hardly been investigated [11]. In an ear-
lier analysis [11] our patient population
was divided a priori into subgroups and
half as large. The purpose of the present
study was to reevaluate the prognostic
relevance of the IASLC classification svs-
tem with regard to propensity for neurolo-
gic complications, including CNS meta-
stases. Therefore, the present retrospecti-
ve study histologic subtyping of SCLC
was related to the findings of prospective
neurologic follow up.
Patients and methods
This study comprised 239 consecutive
patients with a tissue diagnosis of SCLC,
registered at the Department of
Pulmonary Diseases of the University
Hospital Maastricht from October 1980 to
January 1992. Initial evaluation by the
pulmonologist included physical examina-
tion, standard blood and chemistry profi-
le, chest x-ray, bone scan, bone marrow
aspirate and biopsy, ultrasound of the
upper abdomen, and a CT -scan of the
chest and brain. MRI (Magnetic
Resonance Imaging) of the pelvis, spine,
and brain was performed after 1990.
Limited disease (LD) was defined as
tumor confined to the ipsilateral hemitho-
rax, the mediastinum, and the ipsilateral
or contralateral scalene and supraclavicu-
lar lymph nodes. In extensive disease
(ED) the tumor was found beyond these
sites. Patients were initially treated with
chemotherapy, consisting of cyclophosp-
hamide 1000 mg/m2, doxorubicin 45 or 50
mg/m2. and etoposide 100 mg/m2 on days
1, 2, and 3 for at least five cycles.
Radiotherapy to the primary tumor was
applied to all patients until 1982, thereaf-
ter only if local tumor response was par-
tial. Standard criteria of the World Health
Organization were used in the definition
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of responses. Patients who went into CR
were non-randomly treated with PCI, at a
total dose of 30 Gray for the entire cranial
content in 10 fractions of 3 Gray over 2 to
3 weeks. PCI was not used after 1990. All
patients were seen by a neurologist when
diagnosed with SCLC and at quarterly
intervals during the first year, biannually
thereafter. Neurologic complications were
documented using appropriate tests.
Pathology
One of the authors, unaware of the clini-
cal outcome, reexamined the pretreat-
ment histologic or cytologic specimens on
which the original diagnosis was based. All
cytologic specimens were Giesma stained.
The SCLC subtypingof the histologic as
well as the cytologic specimens was done
according to the morphologic criteria pro-
posed by the pathology panel of the
IASLC [16]. In brief, "small cell carcino-
ma" is characterized by oval, round, or
fusiform nuclei with diffusely distributed
chromatin and small nucleoli, nuclear
molding, and indistinct cell borders. The
"mixed small cell carcinoma" is a small
cell carcinoma that contains cells resem-
bling those of large cell lung carcinomas
with a prominent eosinophilic nucleolus
with a paranucleolar halo. The "combined
small cell carcinoma" is SCLC combined
with a more or less prominent component
of squamous or adenocarcinoma.
Statistical analysis
The following statistical procedures were
used to analyze the data: chi-square tests
for comparison of patient subgroups;
logistic regression to investigate the pro-
gnostic significance of age, sex, histologic
subtypes and disease stage with respect
to developing brain metastases. The Cox
proportional hazards model was used to
investigate the prognostic value of the
same factors with respect to brain meta-
static free survival. Survival curves were
estimated by the Kaplan-Meier method,
differences tested by the log-rank test.
Results
Slides from 7 of the 239 patients slides
were not retrievable, while only autopsy
material was available for another 14
patients. In 8 cases the initial diagnosis of
SCLC- was changed to atypical carcinoid
(n = 2), Merckel cell tumor (n= 1),
squamous cell carcinoma (n = 2), adeno-
carcinoma (n = 2) or undifferentiated large
cell carcinoma (n=l ) . These patients
were not evaluated in the statistical analy-
sis. Thus, 210 patients remained for
morphologic subtyping. 187 patients
(85%) were classified as having "small cell
carcinoma" and 31 patients (15%) as
having "mixed cell carcinoma". For the
small cell type the diagnosis was based on
139 histologic slides and 39 cytologic
slides. For the mixed cell type the basis
was 26 histologic and 5 cytologic slides.
Only one patient was classified as having
"combined small cell carcinoma". In the
further statistical analysis mixed and com-
bined subtypes were grouped.
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Age
Gender
Disease
median (range)
n (% subtype)
male
female
stage n (% subtype)
LD
ED
Histologic
small
64 (41-83)
149 (84)
29(16)
69 (39)
109 (61)
subtype
mixed
67 (48-83)
29(91)
3(9)
12 (38)
20 (62)
no subtype
69(49-81)
21 (100)
0(0)
8 (38)
13 (62)
Table 1. Clinical data of 231 SCLC patients classifed by a histologic subtype; small (n=178),
mixed (mixed small cell/large cell n = 31 and combined n=l), and no subtype (no slides available
n = 7 and only autopsy material n=14); KL)=extensive disease.
The clinical characteristics of the 231
patients with SCLC are shown in /»/>/<»• /.
The frequencies of some of these charac-
teristics fluctuated during the 11 years of
follow up. Age, divided into subgroups
(younger than 58, 58-65, 65-73, older than
73), changed with time; until 1982 there
was a relatively high proportion of
patients younger than 58; afterwards the
number of patients younger than 58 and
older than 73 decreased and the number
of patients aged 58-73 increased. The
percentage of female patients increased
over these 11 years, from 0 to 15. The
proportion of small versus mixed subtype
(85/15). and LI) versus KO (40/60)
remained the same over the years. The
response to therapy did not van.' over
these 11 years; about 20-30% of the
patients went into CR. In time, PCI was
increasingly reduced; it was used in 60%
of the patients until 1982, in 15%
between 1983 and 1990, and in none the-
reafter.
The neurologic complications evaluated
at the time of diagnosis and during furt-
her follow up are listed in /tf/Vi"Z
Metastatic complications predominated.
Paraneoplastic complications with a neu-
rologic presentation included pure neuro-
logic paraneoplastic syndromes and neuro-
logic syndromes caused by ectopic hormo-
ne production. In fact the number of para-
neoplastic syndromes in the whole popu-
lation was larger, but these patients had
no neurologic symptoms and were there-
fore outside the scope of this study. The
number of sensory neuropathies was pro-
bably underestimated in the total number
of polyneuropathies; during chemothera-
py many patients complained of tempora-
ry numbness or tingling sensations over
the distal parts of their extremities,
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Neulogic complications: n (%total)
144(100)
Metastatic complications:
•CNS total
•brain
•leptomeningial
•cpidural
Paraneoplastic complications:
•total
91 (64)
61 (42)
18(13)
12(8)
11 (7)
•SIAD11
• Lambert eaton
•cerebellar degeneration
•myelitis transversa
•limbic encephalitis
Other complications:
•total
6(14)
K.7)
1 (.7)
K.7)
2(1.4)
41 (29)
•polyneuropathy
•encephalopathy
•cerebrovascular disease
•myopathy
23 (29)
13(9)
4(3)
K.7)
Table 2. Number (n) and percentage of total (% total) of neurologic complications diagnosed in
210 small cell lung cancer patents; CNS=central nervous system; SIADH=syndrome of inap-
propiate ADH secretion.
mostly without further clinical evidence
of a polyneuropathy or electromyographi-
cal abnormalities. Apart from 2 metabolic
encephalopathies in relatively old and
severely ill patients, 11 possibly PCI indu-
ced encephalopathies were diagnosed.
The possibly PCI induced encephalopat-
hies had an insidious onset within 6
months after termination of PCI. These
involved memory disturbances (n=9),
visual symptoms (n=l),ataxia (n = 2),
and dementia syndromes (n = 2) and were
irreversible, though not progressive for
most of the patients. Myopathy, diagno-
sed in one patient, was induced by corti-
costeroid medication.
33
Histologic subtype
Small cell Mixed cell p value
Complications:
•total CNS metastases
•brain metastases
•Icptomeningeal metastases
•epidural metastases
•paraneoplastic syndromes
n(% subtype)
78(44)
52 (29)
17(10)
9(5)
11(6)
n(% subtype)
13(41)
9(28)
1(3)
3 (9)
0 (0)
n(% subtype)
0.96
0.90
0.19
0.33
0.15
Time periods
(range)
•brain metastatic-free survival 532 (0-3748)
•overall survival 266 (1-3748)
•overall survival for patients
with paraneoplastic syndrome 254 (8-745)
median (range) median
670(0-891)
208(6-891)
0.75
Table 3. Occurencc of mctastatic and parneoplastic complications, and survival data according to
histologic subtype.
Clinical outcome according to histologic
subtype is presented in /tf/Ve J, brain
metastatic free survival curves in //«7//v /.
Statistical analysis yielded no significant
differences in metastatic CNS patterns
(chi-square tests). The percentage of
brain metastases was similar for both his-
tologic subtypes (about 30%). Brain meta-
stases were diagnosed in 13 (26%)
patients with LI) and 49 (38%) with KD.
Upon diagnosis of lung cancer, brain
metastases were present in 9 patients
with small cell type (5%) and 3 patients
with mixed cell type (9%).
Prognostic relevance for developing brain
metastases was investigated with regard
to age, gender, histologic subtype, and
disease stage (logistic regression). Brain
metastases (upon diagnosis of lung cancer
or developed during further follow up)
were less common in older patients
(p = 0.()5) and those with LD (p=0.03).
The occurrence of brain metastases was
not associated with histologic subtype
(p = 0.68) or gender (p=0.25).
The brain metastatic free survival was cal-
culated from the moment of diagnosis of
lung cancer. Histologic subtype, age, and
gender were not significantly associated
with the brain metastatic free survival;
only disease stage was (Cox proportional
hazards model). As expected, LD had a
better prognosis than ED (p=0.0001).
Analysis of the Kaplan-Meier curves with
the log-rank test yielded no differences
for histologic subtype (p = 0.75) or brain
mctastatic free survival. Paraneoplastic
syndromes with a neurologic presentation
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Figure 1. Kaplan-Meier curves of brain mctastatic free survival for histologic subtypes.
were seen mostly in the small cell rype,
but this trend was not significant
(p=0.15). The overall survival of patients
with paraneoplastic syndromes was similar
to that of other patients.
Discussion
Small cell carcinoma of the lung is a
malignant neoplasm with a highly aggres-
sive behavior, resulting in early metastasis
117-19]. The prognosis of patients with
SCLC has been improved by combination
chemotherapy (20]. The presence of
brain metastases is the most frequent
neurologic complication in SCLC and is
associated with poor prognosis. With a
longer survival time these metastases
have become an increasingly important
clinical problem [21-22]. The SCLC is
delineated from other entities in the
neuroendocrine spectrum of pulmonary
neoplasms. At the other end of the spec-
trum, with a low malignant potential, is
carcinoid. In the grey area between SCLC
and carcinoid, several proposals for
nomenclature have been made [23-26].
The most simple subdivision would be
(1) carcinoid, for the classic cases, (2)
neuroendocrine carcinoma instead of aty-
pical carcinoid, in view of its more malig-
nant nature, and (3) SCLC. As yet this
subdivision is not implemented in the last
WHO classification [26]. Since our purpo-
se was to investigate the clinical useful-
ness of the subclassification of SCLC pro-
posed in the consensus report by the
Pathology Committee of the IASLC, we
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restricted this study to SCLC and exclu-
ded the other entities of the neuroendo-
crine spectrum. The IASLC recommen-
dations were intended to provide a repro-
ducible histopathologic subclassification
of SCLC [16]. Since the introduction of
this classification, much research has been
done in evaluating the clinical behavior
and response to therapy of SCLC and its
subtypes. The interobserver agreement
with regard to the diagnosis of the histolo-
gic subtypes was reasonable well in the
study of Fraire et al. [10].
The frequencies with which the different
subtypes were diagnosed in this study is
slightly larger than those reported by
Bcpler et al. [8], Aisner et al. [9], and
Fraire et al. [ 10]. This may be due to pos-
sible differences in sampling and biopsy
size. Their studies suggested that the
mixed cell type is as rare as the combined
cell type and has a frequency of less than
5%. The total number of mixed and com-
bined cell types is not at variance with
these studies. Tumor heterogeneity has
been proposed to be common and to be
more frequent in larger biopsy specimens
and posttherapy or obduction tissues
[2,27,28]. According to Yesner et al. [28],
rhe mixed cell type is found more fre-
quently in larger and less damaged biopsy
specimens. In cases of tumor heterogenei-
ty the use of small biopsies and cytologic
specimens in this study may have led to
differences in subtyping.
The results of this study do not show any
statistically significant relationship
between histologic subtyping and meta-
static CNS pattern, developing brain
metastascs, or brain metastatic free survi-
val. The number of neurologic paraneo-
plastic syndromes was similar to the 3%
reported by Flrington et al. [29]. Because
SCLC is delineated from other entities in
the neuroendocrine spectrum of pulmona-
ry neoplasms and the classic small cell
lines are characterized by higher expres-
sion of neuroendocrine markers than the
variant cell lines [12,14], the assumption
arises that the classic small cell subtype
more frequently predisposes to paraneo-
plastic complications than mixed and
combined subtypes. A slight trend in line
with this hypothesis was found in this
study. Only the classic small cell subtype
was encountered in patients with neurolo-
gic complications due to paraneoplastic
syndromes. This tends to support the
experimental research on SCLC. Other
neurologic non-metastatic complications
were not thought to be associated with
histologic subtyping, but more likely to be
treatment related or coincidental. Our
neurologic data lack clinical significance
with regard to histologic subtyping. This
result supports the outcome of an earlier
analysis of our patient population [11|.
We conclude that histologic subtyping of
SCLC has no implications for CNS meta-
stases. However, the relationship with
paraneoplastic syndromes deserves furt-
her studv.
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/I Diagnostic value of CT in
the detection of brain meta-
stases in small cell lung
cancer patients
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Introduction
Small lung cell carcinoma (SCLC) consti-
tutes 20% of all cases of lung cancer (1),
and central nervous system (CNS) meta-
stascs are an important cause of morbidity
and mortality among these patients (2). A
simple two-stage division is customarily
employed in SCLC. Limited disease
(LD) is confined to the hemithorax of
origin, the mediastinum and the supracla-
vicular nodes. In extensive disease (ED)
tumor is found beyond these sites.
Staging procedures to detect possible
sites of distant metastases are important,
because of different forms of treatment
are given to patients with limited and
extensive disease (3).
Current clinical methods of diagnosis of
brain metastases include physical exami-
nation and cranial computed tomography
(CT). Brain metastases are found in
approximately 10% of newly diagnosed
patients (4). Most of these patients are
symptomatic, and indication for specific
diagnostic methods is determined by the
symptoms and signs (5,6).
CT carried out as a part of routine initial
staging procedure in SCLC patients is not
unanimously considered necessary', parti-
cularly when patients do not show neuro-
logical symptoms. Therefore, this study
was undertaken to determine the value of
a routine cerebral imaging in SCLC
patients in comparison to neurological fin-
dings.
Patients and methods
Between January 1985 and April 1990, 57
patients with SCLC were treated with
chemotherapy according to a prospective
protocol (7). The diagnosis of SCLC was
based on histological and cytological biop-
sy. The subjects, 47 (89%) males and 10
(11%) females, ranged in age from 45-80
(mean age 65). All patients underwent a
neurological examination, a bedside men-
tal status examination, a CT scan of the
brain with and without contrast administ-
ration, and a bone scan. In the group of 57
patients 26 patients had LD, while 31 had
ED. Three (5%) of the 57 patients were
excluded from this study; two of them
had previous cerebrovascular infarcts on
CT and one had leptomeningeal metasta-
ses at the time of presentation. From
January 1985 until February 1989, CT was
performed with a Philips Tomoscan 350,
and from February 1989 until April 1990
with a Siemens Somaton Plus scanner.
Technical data of the Philips machine
were; 120 kV, scan time 4.8 sec, 180 mAs,
slice thickness 9 mm and matrix 512x512.
The images were recorded with a Philips
multiformat camera. Technical data of the
Siemens scanner were: 120 kV, scantime
2 sec, 420 mAs, slice thickness 10 mm
and matrix 512x512. Imaging was perfor-
med with a 3M laser printer. All scans
were at first performed without contrast,
and repeated after intravenous contrast
injection. 100 ml of Telebrix 350 mgl/ml
was used mostly, while in cases with a his-
tory of allergy 100 ml of Hexabrix 320
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Figure 1. CT of the brain (third patient in
table 1). Shows an enhancing lesion in the
head of the left caudate nucleus (arrow 1),
smaller lesions faintley visualized arround
right frontal horn (arrow 2), right frontal later-
al cortex and at the tip of the right occipital
horn (arrow 3 and 4).
mgl/ml was injected. The window settings
in which all scans were printed were: win-
dow width 100 Hounsfield Units (HU)
and Center 40 HI'. The CT findings
were interpreted by a radiologist who had
experience in cerebral CT scanning.
Afterwards the CT scans were indepen-
dently reviewed by neuroradiologist and a
neurologist, and no discrepancies were
found.
Results
Neurological symptoms and signs indica-
ting metastasis were found in 4 patients
out of 54 (7%), w//£. /. Three of these
patients met the CT criteria for cerebral
metastasis, and the abnormalities found
in the neurological examination were ana-
tomically consistent with the abnormali-
ties on the CT scan, see toM» /.
Bone scans revealed no abnormalities of
the skull. One patient with neurological
symptoms and signs showed no evidence
of brain metastasis on CT. However, six
months later, this patient's CT scan indi-
cated brain metastasis. In the remaining
group of 50 neurologically asymptomatic
SCLC patients no sign of cerebral meta-
stasis was seen on CT.
Discussion
The value of routine cerebral cerebral
scanning in SCLC patients is controver-
sial. The literature presents conflicting
data on the question whether patients
without neurological symptoms should
undergo CT of the brain. Levitan et al.
(8) found that in 3 out of 44 (7%) SCLC
patients with LD tumor, the stage was
altered by the use of CT as a routine pro-
cedure. Crutz et al. (9) recommended
routine CT scanning as part of the initial
staging of patients with SCLC. He found
that 6 neurologically asymptomatic
patients out of 99 (6%) patients with LI)
had been upstaged to MI). Butler et al.
and Johnson et al. studied neurologically
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Patient nr.
gender, age
1. Male 75
2. Male 52
3. Female 69
4. Male, 59
Classification
ED
ED
ED
ED
Clinical
presentation
•headache
•vertigo
•headache
•vision R eye I
• ptosis R eye
•paresis R leg
•headache
•papilledema L/R
•vision L/R 1
Cranial CT
single metastasis
multiple metastasis
multiple metastasis
no metastasis
Table 1. Symptomatic patiens with SCLC and frequences of brain metastasis; ED: extensive
disease; L=lcft; R=right; SCLC= small cell lung cancer; CT=computer tomography.
intact SCLC patients and found brain
metastases in three out of 55 (5.5%) and
two out of 84 (2%), respectively. Both
authors conclude that routine cerebral
imaging is advisable in these patients.
Because of the low incidence of CNS
metastases at the time of diagnosis in
asymptomatic SCLC patients, we doub-
ted the benefit of routine cranial CT. In
our study 4 (7%) of the 54 SCLC- patients
showed evidence of neurological symp-
toms and signs, which was confirmed in 3
patients with CT. In one symptomatic
patient no brain metastasis was found on
the CT scan at the time of presentation.
I lowcver, six months later CT indicated
brain metastasis. We believe that CT was
not sensitive enough in this patient to
detect the initial small lesions. In such
cases we would suggest MR1 which is
superior in detecting subtle lesions
(10,11).
Although plain MRI carries the risk of
false positive interpretation of non-neo-
plastic age-related parenchymal lesions in
the elderly (10,11), contrast enhanced
MRI using gadolinium DTPAcan diffe-
rentiate between areas of altered signal
intensity due to widening of the perivas-
cular spaces and areas containing metasta-
ses (12). It appears likely that contrast
enhanced MRI will become the method
of choice for detection of cerebral meta-
stasis.
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In our study, as a rule, all SCLC patients
were examined by a neurologist, and no
brain metastases were discovered in neu-
rologically normal patients. We conclude
chat CT scanning of the brain at the ini-
tial stage of SCLC does not contribute
additional diagnostic information to a
careful neurological examination.
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£ Diagnostic value of MR ima-
ging in the detection of
brain metastases at initial
staging in small cell lung
cancer
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Introduction Patients and methods
Small cell lung carcinoma (SCLC), which
accounts for approximately 25 per cent of
the cases of lung cancer, has a highly
aggressive behavior, resulting in early
metastasis [ 1 ]. The prognosis of patients
with SCLC has improved with chemothe-
rapy [2|. The occurrence of brain meta-
stases is the most frequent neurological
complication in SCLC, and is associated
with a poor prognosis [3,4].
Prior to the advent of magnetic resonance
(MR) imaging, neurological examination
and cranial computed tomography (CT)
were used as screening procedures for
brain metastases [5-8|. More recently, the
use of a contrast agent such as gadolinium
DTPA has extended the role of MR ima-
ging in the evaluation of brain metastasis
and making MR imaging superior in sensi-
tivity and specificity to the CT-scan for
the detection of brain metastasis [9,10].
The value of MR imaging of the brain as a
screening procedure in patients with
SCLC has not been adequately studied.
To assess the value of routine MR ima-
ging in the staging work-up of patients
with small cell lung cancer, we studied
the correlation of MR findings with the
neurological examination in 40 patients
with small cell lung cancer.
Subjects
Between May 1991 and March 1994,40
patients with newly diagnosed SCLC
were included in the study. The diagnosis
of SCLC was based on histological or
cytological biopsy. To detect areas of dis-
tant metastases, ultrasound and CT of
the abdomen, radionuclide bone scan, MR
bone scan and bone marrow aspirates
were routinely performed. Limited disea-
se (LD) was defined as tumor confined to
one hemithorax with or without ipsilateral
mediastinal or supraclavicular lymph node
involvement. Patients with cxtrathoracic
tumor spread beyond these sites were
classified as having extensive disease
(ED).
Treatment and clinical assessment
In the course of evaluation, all patients
were routinely referred to the department
of neurology for an assessment of possible
neurological metastases. All patients
underwent a neurological examination.
Patients were prospcctively evaluated by
a neurologist every three months for the
first year, and biannually thereafter.
Follow-up cranial MR scans were perfor-
med on indication only. The patients
were followed until death or for at least
three months.
MR imaging
MR imaging of the brain was performed
within one month (in 85% of the patients
46
within two weeks) after the pathological
confirmation of SCLC. MR imaging was
performed with a 0.5T system (Philips
Gyroscan II). First a set of transverse T2-
weighted images was obtained. In the
first 38 examinations a conventional spin-
echo sequence (TR 3-3.5 seconds, TE
120 msec FOV 230 mm, 5 mm slices
205x256 matrix, NSA1) was used. All later
examinations featured a fast spin-echo
sequence (TR 4.5-6.5 sec, TE 130 msec,
FOV 230 mm, 241x256 matrix, NSA4,
echo train length 16). Tl-weighted spin-
echo images were obtained (TR 600
msec, TE 18 msec FOV 230 mm, 10 mm
slices 205x256 matrix, NSA4) before and
after IV injection of the MR contrast
medium gadolinium DTPA (MagnevistR)
in a dosage of 0.1 mmol/kg.
MR findings were classified into four
groups according to Elster 111) :1) normal
scans; 2) scans with unequivocally benign
lesions (infarctions, arachnoid cysts etc.)
that harboured no suspicion of metastatic
disease; 3) scans with at least one enhan-
cing lesion compatible with a metastasis;
and 4) scans with one or more hyperinten-
sities of the deep and subcortical white
matter and periventricular hyperintensi-
ties. none of which enhanced after con-
trast injection.
The MR findings were interpreted by a
neuroradiologist (JTNV) with extensive
experience in cerebral MR and were later
blindly reviewed by the same neuroradio-
logist together w ith a neurologist (AT)
No discrepancies were found between the
first and second assessments.
Results ' '*
Forty patients had both a neurological
examination and an MR examination .
Motion artefacts occurring in one agitated
patient led to premature termination of
the MR examination. This patient was
excluded from the study population. Of
the remaining 39 patients, 15 patients
were staged by the pulmonologist as
having limited disease, while 24 patients
were staged as having extensive disease.
The patients, 30 males and 9 females,
ranged in age from 31-78 years (median
age 62).
The MR findings are summarized in
/&AW. Of the 12 patients (31%) with nor-
mal MR examination (group 1), one
patient with a history of chronic headache
and transient ischemic attacks had
recently developed difficulties with con-
centration. Clinical follow-up revealed no
signs of brain metastases.
At the time of the MR imaging study, two
patients (5%) with previously documen-
ted cerebrovascular diseases from group
2(benign lesions) had non-enhancing
white matter lesions, which where confi-
dently interpreted as non-metastatic.
Eleven patients (28%) had MR results
which were interpreted as positive for
tumor metastases (group 3). The neurolo-
gic deficits detected by neurologic exami-
nation were anatomically consistent w ith
the MR findings. Three ED patients had
asymptomatic brain metastases.
47
MRI neurological examination
abnormal / normal
brain metastases
within 6 months
group 1
group 2
group 3
group 4
12
2
11
14
1/11
2 / 0
8 /3
4 / 1 0
0
0
11
2
Table 1. Magnetic resonance imaging and clinical findings in 39 patients with small cell lung can-
cer.Magnetic resonance imaging (MRI) findings were classified into four groups: group 1 = nor-
mal; group 2 = benign lesions (two patients with cerebral infarctions); group 3 = metastasases
(three patients were asymptomatic); group 4 = non-enhancing white matter lesions (two of the
four symptomatic patients developed brain metastases within six months, one patient after ten
months).
Of the 8 ncurologically symptomatic
patients, 3 had no other signs of extra-
thoracic tumor activity and were initially
classified by the pulmonologist as having
limited disease. The classification was
later changed to extensive disease on the
basis of neurological consultation and MR
findings.
Four of 14 patients (36%) from group 4
(non-enhancing white matter lesions) had
neurologic symptoms and signs but
showed no MR evidence of brain metasta-
ses. One patient with a brief history of
frontal headache and atypical brachialgy
at initial neurologic examination, did not
develop brain metastases and turned out
to have tension headache and a carpal
tunnel syndrome. However, 3 of the 4
symptomatic patients were found to have
developed brain metastases by follow-up
MR imaging. The MR scan of the first
patient demonstrated enhancing brain
metastases two months later, with a
rapidly progressive decline. The second
patient, with left sided facial weakness
and hyperreflexia of the left arm, develo-
ped an unstable gait and became progres-
sively confused three months later. Then
months after initial staging, the third
patient, with a brief history of atypical
pain, developed signs of raised intracranial
pressure and cerebellar ataxia. As shown
in//£wr /, some of the initially non-
enhancing white matter hyperintensities
increased in volume and showed contrast-
enhancement at follow-up examination.
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Figure I. Magnetic resonance imaging of the brain in a 51-year old patient with neurological
abnormalities at initial staging.
Figures A and B were obtained before treatment, figures C and D after neurological deterioration
three months later; A T2-weighted image shows deep white matter hyperintensities; B T l -
weighted image after Gd-DTI'A injection do not show enhancement; C T2-weighted image once
again shows deep white matter hyperintensities; D Tl-weighted image after Gd-DTPA injection
shows obvious contrast-enhancement.
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Discussion
The major goals of staging patients with
SCLC are to provide prognostic informa-
tion and to select the best treatment.
The value of routine cerebral imaging in
SCLC patients is controversial, because
CT has failed to detect some metastases,
especially those which are in the posterior
fossa. The literature presents conflicting
data on the question whether patients
without neurological symptoms and signs
should undergo CT of the brain [6,7]. We
have found that CT is not sensitive
enough in asymptomatic patients and
need therefore not be a part of the routi-
ne staging procedure in small cell lung
cancer |<S|.
The advent of magnetic resonance ima-
ging has had a profound effect on the eva-
luation of central nervous system (CNS)
tumors; it offers marked advantages over
CT and provides superior definition of a
CNS tumor, particularly if a paramagnetic
contrast agenr^  is used. Contrast CT and
non-contrast MR imaging are roughly
comparable in the detection of brain
metastases. Post-contrast MR imaging,
however, have an increased accuracy,
compared with contrast-enhanced CT,
particularly in the detection of metastases
in the posterior fossa and cortex (9,12).
The value of contrast-enhanced MR ima-
ging of the brain at initial staging in
patients with SCLC has not been studied
in the past. In the present study, brain
metastases were found in 11 patients of
the 39 patients (28%), depicted as con-
trast-enhancing lesions on initial MR ima-
ging. Prior CT studies have demonstrated
a 5 to 27% incidence of brain metastases
at diagnosis of SCLC [5-8]. Magnetic res-
onance imaging revealed brain metastases
in three neurologically asymptomatic
patients in our study. However, these dis-
crepancies did not affect the clinical sta-
ging, as the patients concerned were alre-
ady known to have extensive disease on
base of other extrathoracic metastases.
In the present study, non-enhancing
white matter lesions were seen in 14
patients. Four of these patients were neu-
rologically symptomatic and in three of
them, the initially non-enhancing white
matter lesions later changed into contrast-
enhancing lesions, compatible with brain
metastases. It therefore appears that con-
trast-enhanced MR imaging may under
report some early metastases, which are
obscured from view by high-signal white
matter lesions on T2-weighted images
and do not yet show contrast-enhance-
ment on Tl-weighted images.
Early investigators observed that MR ima-
ging brings to light a high frequency of
white matter abnormalities that cannot be
related to clinical findings and could not
previously be detected (13-15).These
appear as bright areas on both proton den-
sity and T2-weighted images. Their sizes
range from small foci to large confluent
lesions, and they vary in extent and loca-
tion. White matter hyperintensities in
neurologically asymptomatic patients van-
in frequency from 11% in the fourth deca-
de to 65% in the seventh decade [14].
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Fazekas et al found that deep white mat-
ter hyperintensiries reflect increasing
severity of ischemic tissue damage, the
most likely substrate of white matter
hyperintensities in elderly patients [15].
Some investigators have assumed that
lesions of the subcortical, deep and peri-
ventricular white matter on T2-weighted
images were not brain metastases if they
did not enhance with contrast agent used
in combination with Tl-weighted images
(9,10). Elster et al found that white mat-
ter lesions in cancer patients which not
enhance with Gadolinium-DTPA at the
time of the initial MR study had a low
probability of representing metastatic dis-
ease and suggested that in questionable
cases, follow-up scans should help to dif-
ferentiate them from metastases (11).
Our findings, however, showed that ini-
tially non-enhancing white matter lesions
can develop into brain metastases. The
earliest MR manifestation of metastatic
disease in the brain is not known. It is
unclear whether this earliest manifesta-
tion of metastatic disease is contrast
enhancement or a high signal T2 abnor-
mality, reflecting increased tissue water
content rather than contrast accumula-
tion.
In conclusion, MR imaging is a sensitive
tool in the detection of brain metastases
at initial staging of SCLC-patients, since
brain metastases were visualized in three
neurologically asymptomatic patients.
The combination of MR imaging and cli-
nical findings is of value in preventing
false-negative diagnosis. When cerebral
metastases are suspected on clinical
grounds and MR imaging shows only non-
enhancing white matter lesions, the best
course of action would be to perform neu-
rological and neuroradiological follow-up.
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Introduction ,y-f
Brain metastasis is a well recognised com-
plication in small cell lung cancer
(SCLC). Approximately 0-16% of the
patients have brain metastases at initial
diagnosis, 0-32% subsequently develop
brain metastases during treatment, and
28-64% have brain metastases in various
post-mortem studies 11 ]. The risk of
brain metastasis increases with lengthe-
ning survival, to a cumulative risk of 80%
in patients at 2 years after diagnosis [2].
Though combination chemotherapy with
or without locoregional radiotherapy has
yielded complete or partial responses in
80-90% of all patients, median survival is
limited to 11-16 months depending on
the initial tumor stage [3]. Prophylactic
cranial irradiation (PCI) is effective in
reducing the central nervous system
(CNS) relapse rate |4].
However to date, no randomized trial
showed any PCI survival benefit [4]. And
its use has become controversial as PCI
potentially contributed to CNS-toxicity
in SCLC patients [4-10, 16]. PCI failure
with regard to survival is probably explai-
ned in that CNS relapse in the majority of
the patients is associated with recurrence
or progression of systemic disease. The
CNS as sole site of relapse is only seen in
3-4% of the patients [11]. However, PCI
administration becomes interesting again
with the development of new treatment
protocols with increased median survival
time and increased 2 year survival rate
H2-I41.
In this study, we present the results of a
neurologic follow-up of a cohort of 203
consecutive patients with SCLC. The
efficacy of PCI is analysed for limited
stage patients who achieved complete
remission, whereas all patients given PCI
are evaluated for possible adverse effects
of PCI. Furthermore the neurologic con-
dition of 18 patients who survived the
diagnosis of SCLC for more than 2 years
is described in detail.
Patients and Methods
From January 1983 to January 1993, 203
consecutive patients with histologically
proven SCLC were included in this pro-
spective study. Minimal follow up was 1
year or until death, till January 1994.
Initial staging of these patients by a pul-
monologist, was based on physical exami-
nation, standard blood and chemistry pro-
file, chest x-ray, CT-scan of the chest,
ultra-sound of the abdomen, radionuclide
bone scan, fibre optic bronchoscopy, and
bone marrow aspirate and biopsy. Limited
disease (LD) was defined as tumor confi-
ned to the ipsilateral hemithorax, the
mediastinum, and the ipsilateral and/or
contralateral scalene and supraclavicular
lymph nodes. In extensive disease (ED)
tumor was found beyond these site.
Patients were seen by a neurologist at
diagnosis and at quarterly intervals (bi-
annually after a year). A CT-scan of the
brain, MR imaging after 1991, was perfor-
med before treatment.
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More frequent neurologic consultations
and other auxiliary diagnostic tests were
done if required. In patients with a long-
term survival (defined as 2 years or longer
from diagnosis) an additional CT- or MR-
scan of the brain was performed. Central
nervous system abnormalities found in
patients treated with PCI, were designa-
ted as possibly treatment related unless
otherwise clearly explainable.
All patients were initially treated with a
combination chemotherapy regimen, con-
sisting of cydophosphamide 1000 mg/m2,
doxorubricin 45 or 50 mg/m2, and etopos-
idc 100 mg/m2 on day 1,3, and 5 for at
least five cycles. Chemotherapy was
sometimes followed by radiotherapy to
the primary tumor site. Restaging was
performed after five courses of chemothe-
rapy and consisted of physical and radiolo-
gical examinations, fibre optic broncho-
scopy, and those examinations which were
abnormal at the initial staging procedure;
complete remission (CR) was defined as a
total resolution of all detectable lesions.
Only patients who obtained CR were can-
didates for treatment with PCI. Till 1986
LI) and ED patients could opt for PCI,
after 1986 LI) patients only. Patients
were treated with a linear accelerator,
usually 6 MV photons, using two lateral
opposed fields. The dose was calculated
in the midline, and delivered in daily frac-
tions of 3 Gy, 4 times a week up to a total
dose of 30 Gy. During 1988 - 1990 the
radiation technique was changed as the
fraction dose was lowered to 2 Gv, 5 frac-
tions a week up to a total dose of 30 Gy.
In 1990 PCI was excluded from the treat-
ment protocol. Between 1983 and 1990,
two eligible LI) patients refused PCM.
Patient characteristics and treatment spe-
cifications are listed in table 1.
The efficacy of PCT was analyzed for LD
patients with CR only. Statistical signifi-
cance of the incidence of brain metastasis
was calculated with the Fisher's exact
test, of the survival curves with the log
rank test. Overall survival was calculated
from SCLC diagnosis to death or end of
observation period, brain metastatic free
survival from SCLC diagnosis to the diag-
nosis of brain metastases or end of obser-
vation period. The safety of PCI was eva-
luated for all patients who achieved CR
and were treated with PCI. The neurolo-
gical condition of the long-term survivors
(defined as 2 years or longer from diagno-
sis) is described in detail, in particular
with regard to adverse reactions of PCI.
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Patients .
total
men / women
median age at diagnosis (range)
complete remission
prophylactic cranial irradiation
Disease stage
limited
74
59/15
64 (39-84)
37
17
extensive
129
111/18
65 (45-89)
30
5
Table 1. Patient characteristics.
Results
Efficacy of PCI
Kfficacy of PCI was assessed in 37 LI)
patients who achieved CR. Brain metasta-
ses were diagnosed in 3 of 17 patients tre-
ated with PCI versus 8 of 20 patients not
treated with PCI. The number of brain
metastases did not differ significantly
(p=0.26). The brain metastatic free sur-
vival curves are shown in//"w/r /, and the
overall survival curves in//«7//v.?. For the
analysis of the survival curves leptomenin-
geal metastases were considered as brain
metastases for statistical reasons; two of
the 5 patients with brain metastasis after
PCI actually had leptomeningeal metasta-
ses. Log rank analysis of survival curves
revealed significant differences between
patients with and without PCI. Patients
treated with PCI had a longer brain meta-
static free survival (p = 0.012) as well as a
longer overall survival (p=0.004) than
patients not treated with PCM.
The majority of the patients (30 patients
or 81%) had an intrathoracic SCLC recur-
rence, see taM?Z Brain metastases were
diagnosed after systemic recurrence of the
disease in 7 patients. Systemic recurrence
was established within 1 month after the
diagnosis of brain metastases in 3 other
patients. The brain as sole site of relapse
was seen in 1 patient who was treated
with PCI. New malignancies [1 non-
SCLC and 1 Non Hodgkin Lymphoma]
were diagnosed in 2 patients. Only 3
patients (8%) had no relapse. The exact
cause of death remained unknown in 1
patient.
Safety of PCI
Safety of PCI was assessed in 17 LD and
5 ED patients treated with PCI between
1983 and 1990. Early neurologic sequelae
were seen till three months after PCI; 7
of the 22 patients experienced headache
and nausea during PCI, another 5 patients
reported with a brief period of increased
tiredness.
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proportion brain metastatic free surviving
'JJ
• . . - . . . . • " - • ? , • . • ; ' ! . » . •
1.0-1
0 . 8 -
0.6 _
0.4 _
0 . 2 -
0.0 _
Figure 1. Brain metastatic free survival in weeks; 6 patiens in PCI group were still at risk past 200 weeks.
proportion surviving
1.0 I
0.8.
0.6.
0.4 _
0.2.
0.0 _
0 5 0
figure 2. Overall survival in weeks; 1 patient in PCI group passed away at 417 weeks, 1 is still at risk.
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Patients PCI no PCI
total
median age (range)
radiotherapy primary tumor
median survival (range)
Relapse
lung
lung and CNS
sole CNS
new malignity
none
unknown
17
56 (42 - 78)
6
18(7-132)
6
4*
1
2
3
1
20
68 (48 - 84)
5
13(7-19)
12
8
0
0
0
0
Table 2.Outcome of 37 limited disease patients with complete remission.
Age is in years and survival in months; PCI = prophylactic cranial irradiation;
CNS = central nervous system: * 2 of these patients had leptomcningeal metastases.
Of the original group of 203 patients 18
patients (9%) survived for more than two
years. Their neurologic outcome is pre-
sented in /<y/>/i"J. Four patients, all not tre-
ated with PCI remained without neurolo-
gic complications. Possible treatment
related neurologic complications arose in
7 patients with PCI and 1 patient without
PCM. Other, non treatment related, neuro-
logic complications comprised brain meta-
stases in 3 patients, cerebrovascular acci-
dent in 2 patients, and paraneoplastic
subacute cerebellar degeneration in 1
patient.
Memory disturbances surfaced as the
most frequent possible treatment related
complication in 8 patients (7 with and 1
without PCI). Immediate recall was usu-
ally affected. The memory decline was
insidious and started in 6 patients within
6 months after termination of therapy and
in 2 other patients after 18 months. Once
established the memory disturbances
remained stable for months to years in
most of the patients. Memory disturban-
ces were accompanied by lethargy or a
generalised lack of energy in 4 patients.
Although the lethargy, in these patients,
started simultaneously with the memory
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Patients PCI no PCI
total
men/women
median age at diagnosis (range)
median survival (range)
Neurologic complications
none
possible
other
Radiologic abnormalities
none
possible treatment related
other
9
7/2
55 (52 -67)
40(25- 120)
0
7
2
2
5
2
9
6/3
60 (45 - 74) ,c
27(24-56) '
4
1
4
2
3
4
Table 3. Neurologic outcome of long-term survivors.
Age is in years and survival in months; PCI = prophylactic cranial irradiation. Outcome is
divided over three categories, with no, possible treatment related, and otherwise explainable
neurologic complications or radiologic abnormalities, respectively.
disturbances, the course was more unpre-
dictable; two patients improved and two
patients developed a progressive apathy
combined with drowsiness, in one of them
resulting in a full blown dementia syndro-
me.
In 3 of 9 patients without PCI, possible
treatment related radiologic abnormalities
were manifest; 1 patient with memory'
disturbances had aspecific white matter
lesions, and in 2 other patients though
neurologically normal brain atrophy was
present.
Of 9 patients receiving PCI treatment 5
had possible treatment related radiologic
abnormalities. These 5 are broken down
as follows: 1 patient suffering from memo-
ry disturbances, developed visual com-
plaints 7 years post treatment. The com-
plaints consisted of distortions and disco-
lorations in her visual field.
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Together with the visual complaints her
walk became unstable. Brain MR scan
showed aspecific white matter lesions
right sided parieto-occipital but was
otherwise normal. Two patients (one with
memory disturbances and another with
memory disturbances and non progressive
lethargy) had brain atrophy, and finally 2
patients (with memory disturbances and
progressive lethargy) manifested brain
atrophy as well as periventricular white
matter lesions, normal follow-up scans.
Outside of these 5 patients, 2 PCI
patients had possible treatment related
neurologic complications (one with
memory disturbances and another with
memory disturbances and non progressive
lethargy) and normal follow-up scans.
Of the 8 long-term survivors with possible
treatment related neurologic abnormali-
ties 5 (4 with and 1 without PCI) expe-
rienced minor neurologic deficits (memo-
ry disturbances), and 3 were seriously
handicapped by these deficits (2 patients
with a progressive lethargy, and 1 patient
with visual complaints and an unstable
gait). All other patients were capable of
basic self care and resumed a lifestyle
more or less similar to that before diagno-
sis of SCLC. Some patients concluded
their working life earlier, because of
impaired physical rather than neurological
condition.
Discussion
An analysis of 9 randomized trials by
Pedersen et al [4] revealed a reduction of
the accumulated frequency of clinical
brain metastases from 23% without PCI
to 6% with PCI, but no improvement in
overall survival. The total population of
71ft patients in this analysis was rather
heterogeneous as some studies included
patients who did not achieve CR, and
patients with ED. Furthermore these stu-
dies were, as far as reported, different
with regard to the follow-up time. Rosen
et al [15] demonstrated an increased sur-
vival with PCI in patients responding
completely. Fleck et al [16] analysed 58
LI") patients who went into CR and found
significantly fewer overall CNS relapses in
patients treated with PCI, though the dif-
ference between initial CNS relapses was
small and the disease-free survival, and
overall survival did not differ significantly.
PCI appears to have been effective in
increasing survival of LD patients who
achieved durable thoracic control in a
study by Rosenstein et al [17]. In the pre-
sent neurologic follow-up study, PCI had
no impact on the frequency of brain meta-
stases whereas the brain metastatic free
survival and overall survival improved sig-
nificantly. However, these results should
be interpreted carefully as the number of
patients is small and it is a non-randomi-
zed study. Locoregional treatment
differed slightly for patients treated with
and without PCI. Radiotherapy to the pri-
mary tumor was administered to 6 of the
17 patients treated with PCI (35%) and 5
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of the 20 patients not treated with PCI
(25%).
Hirsch et al [18] showed that 33% of the
patients had "silent" brain metastases, in
a study in which clinical and autopsy fin-
dings were compared. In this study, the
clinical diagnosis of brain metastases
hecame more reliable by regular neurolo-
gic examinations and the use of modern
imaging techniques, although it remained
clinically difficult to establish the extent
to which metastases are restricted to the
CNS. Isolated CNS metastases can repre-
sent seeding from a previously undetec-
ted intrathoracic relapse. In the present
study, a sole CNS relapse was seen in 1
patient treated with PCI only. The majo-
rity of the patients had a systemic recur-
rence of disease before or shortly after the
diagnosis of brain metastases, which can
represent new seeding as well as growth
of already existing microscopic brain
metastases. So rather than PCI treatment
failure, brain metastasis may indicate the
non-effectiveness of chemotherapy and
locoreginal therapy. The same goes for
the differences in brain metastatic free
and overall survival, which are equally
related to the recurrence of systemic dise-
ase.
The administration of PCI in combination
with systemic chemotherapy is potentially
neurotoxic; a wide range of neurologic
abnormalities have been reported
together with the occurrence of white
matter changes and brain atrophy (dis-
played by ventricular dilatation as well as
widening of sulci), particularly in long- t
term survivors [4-10, 16]. Pedersen et al
[4] concluded from the combined data of
8 relatively small retrospective studies
with a total of 123 long-term survivors of
whom 102 patients received PCI that 45%
had severe clinical CNS defects. The sig-
nificance and frequency of the possible
treatment related CNS abnormalities
varied strongly in different studies. Most
of the existing studies have attributed
unexplained neurologic conditions follo-
wing treatment to neurotoxicity of the
chemotherapy and PCI combination, wit-
hout clearly defining them. Johnson et al
[9] studied 20 long-term survivors and
found an increased CNS toxicity when
PCI was administered in larger fraction
doses or concurrent with chemotherapy.
In the present study, PCI was delivered
after termination of the systemic chemo-
therapy. Possible treatment-related neu-
rologic complications and scan abnormali-
ties were diagnosed more frequently in
long-term survivors treated with PCI than
long-term survivors not treated with PCI;
7/9 versus 1/9 neurologic complications
and 5/9 versus 3/9 radiologic abnormalities
respectively. In contrast with studies
where chemotherapy has followed by or
been concurrent with PCM [7-9, 16] and
consistent with a study in which PCI was
applied after chemotherapy [10), the neu-
rologic complications were relatively mild
for the majority of the patients.
Brain irradiation in combination with or
without chemotherapy is hazardous for
the CNS and white matter in particular
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119]. White matter changes are more sen-
sitively imaged by MRI as focal hyperin-
tensities of the central white matter [20,
211 than by CT. Some researchers have
concluded that these white matter abnor-
malities are normal age related changes
[22-25], while others suggested a marked
relation with hypertension [26-29]. In a
prospective study which was conducted to
explore the value of routine cranial MR
scanning as a pretreatment screening pro-
cedure in patients with SCLC, white
matter hyperintensities were found in 14
(36%) of 39 patients who varied in age
from 51 to 78 years [30]. As patients were
primarily evaluated with CT-scan, the
white matter abnormalities seen on MR
scans of long-term survivors in this study
cannot be attributed a priori to radiation
damage. The higher frequency of possible
treatment related radiologic abnormalities
in long-term survivors treated with PCI is
partially explained by the longer follow-up
time, because radiation induced CNS
changes tend to be irreversible and
progressive over time [19). Therefore, the
possible treatment related radiologic
abnormalities do not necessarily confirm
the association of PCI, in the present
study.
ment related adverse effects, though rela-
tively mild, were seen more frequently in
long-term survivors treated with PCI. '
The higher frequency of adverse effects
might be explained by a longer follow up
and differences in imaging technique.
However, every adverse effect of PCI is
valid as long as the efficacy of PCI is not
clearly established. The results of this
study confirm the general belief that PCI
may be effective by increasing the brain
metastatic free survival, and its use with
systemic chemotherapy bears the risk of
CNS toxicity.
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Introduction
The current treatment regimen of
patients with small cell lung cancer
(SCLC), including systemic chemothera-
py with or without chest irradiation and
prophylactic cranial irradiation (PCI), is
potentially neurotoxic. Prophylactic cra-
nial irradiation in particular has been bla-
med for adverse effects on the central
nervous system (CNS) and its administra-
tion has become controversial
(19,3,10,11,13,12,6,7,21).
The white matter of the CNS is especial-
lyvulnerable to radiation (1,2,18,14,4)
Chemotherapy can by itself induce white
matter injury, as well as enhance the toxic
effects of radiation. Computed tomogra-
phy and magnetic resonance studies have
shown evidence of both white matter and
cortical atrophy (18,14,4). Clinically, the
neuroanatomic changes seen by computed
tomography or magnetic resonance are
associated with impairment of mental
function, seizure disorders, and motor
abnormalities. The most prominent clini-
cal features, however, involve impairment
of cognitive functioning (2,14).
In the present study, the results of a neu-
rologic and neuropsychologic follow-up of
a group of consecutive patients with
SCLC arc reported. The purpose of the
current investigation was to establish
early signs of cognitive dysfunction by a
neuropsychologic follow-up. The neuro-
psychologic test batten, was designed to
allow group comparisons of neuropsycho-
logic functioning on different domainsrat-
her than the diagnosis of specific deficits
in individual patients. The present study
also compared patients in their prethera-
peutic condition with matched controls in
an attempt to distinguish between the
impact of disease and treatment related
factors.
Methods and materials
Thirty two consecutive SCLC patients
were enrolled in a prospective study. All
patients were initially treated with che-
motherapy, consisting of cyclophosphami-
de 1000 mg/m2, doxorubicin 45 mg/m2,
and etoposide 100 mg/m2 on days 1, 3,
and 5 for five cycles. After chemotherapy,
patients in complete remission received
PCI, in a total dose of 30 Gy on the entire
cranial content, in 15 fractions of 2 Gy
over 2 to 3 weeks. Patients were seen by a
neurologist upon diagnosis and at quarter-
ly intervals thereafter (biannually after a
year). A computed tomography scan of
the brain was performed before treat-
ment. More frequent neurologic consulta-
tions and other ancillary tests were done
as required. Patients with brain metasta-
ses were excluded from the analysis.
Complete neuropsychologic evaluation
included history, observation, and esta-
blished procedures for testing intelligen-
ce, mental control, information processing
speed, visuo-motor speed, verbal and visu-
al memory, fine motor functions, and eye-
hand coordination. Intelligence was tes-
ted pretherapeutically with the Groninger
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lntelligentie Test (17), a Dutch-language
standardized intelligence battery. Mean
results on the Dutch version of the 15
Word auditor.- verbal learning test (15)
the Stroop color-word test (15), and the
Trailmaking test parts A and B (15) were
analyzed, as for these tests, control data
were available (9). Patients in prethera-
peutic condition (session 1) were compa-
red to controls, who were matched for
age, gender, and educational level (16).
Tests were repeated during chemothera-
py (session 2), after chemotherapy (ses-
sion 3), 1 month after PCI (session 4),
and 5 months after PCI (session 5).
For the Trailmaking test, subjects are
asked to connect successive numbers
(part A), or alternating successive num-
bers and letters (part B) on a card (15). In
the Stroop test subjects have to read color
names (word), name colors (color), and
read color names printed in a different
color (color-word); during the color-word
part of the test, subjects have to inhibit
automatic reading responses, which cau-
ses a delay (interference effect) compared
to the color part of the test (15) In the 15
word test, subjects are presented the
same series of 15 words five times and are
asked to reproduce these words after each
presentation, as well as after 20 minutes.
After the last spontaneous recall they are
asked to recognize the 15 target items
from a list of 30 words (15). Total recall
capacity over five trials (total), difference
between the worst and the best score over
five trials (delta), the delayed recall, and
the recognitionare analyzed. The relevant
measure in the Trailmaking and Stroop
tests is the performance speed.
Patient characteristics are listed in 7iv/V<"
/. None had a history of severe head inju-
ry or chronic intoxications (alcohol or psy-
choactive drugs). Brain metastases were
diagnosed in 3 patients at the onset of
SCLC and in 11 other patients during the
course of the disease. Four other patients
were excluded from further analysis, as
they had not been neuropsychologically
tested before the start of chemotherapy.
Three patients with rapidly progressive
SCLC died within the first 6 months.
Therefore, the number of patients was
reduced from 14 in the first two test ses-
sions to 11 in the third test session. Only
5 patients were treated with PCI. The
sample t-test was used for statistical ana-
lysis of the mean test results.
Results
Regular neurologic examination revealed
no CNS abnormalities in patients without
evidence of CNS metastases. All patients
without evidence of rapidly progressive
disease or CNS metastases remained
ambulatory and capable of self care. Some
patients complained about concentration
problems, difficulties in recalling telepho-
ne numbers, slight word finding problems,
and loss of libido. These complaints were
heard at diagnosis, as well as during the
course of the disease, when specifically
asked.
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nmale
limited
disease
Total
32
26
12
Session 1
14
12
4
and 2 Session3
11
9
1
Session 4 and 5
5
-4
3
age mean
(range) 64(45-78) 63(51-73) 64 (54-73)
IQ mean
(range) 103(71-129) 103(87-116) 103(87-116)
58 (52-62)
101 (95-110)
Table 1. Patients charateristics: total=all patients enrolled; session 1 and 2 = pretherapeutic
and during chemothcrapic; session.}=after chemotherapy; session 4 and 5=one and five
months after prophylactic cranial irridation; IQ=intelligence quotient.
The analysed neuropsychologic tests in
the study measure aspecific effects of
brain dysfunction, where perceptual-
motor speed, attention span, flexibility,
and memory are concerned. The mean
results on the Dutch version of the 15-
Word auditory verbal learning test (15)
the Stroop color-word test (15) and parts
A and B of the Trailmaking test (15) are
shown in 7<Y/>/C.?. The mean results scored
on these tests by the patients in prethera-
peutic condition were significantly worse
than those of matched controls (p <
0.001). The test results did not show any
significant deterioration during or after
chemotherapy, nor after PCI (0.1 < p <
0.8). In the 5 patients taking part in all
the test sessions, the changes of the
various test items throughout time did
not show a consistent pattern, yet were
more indicative of improvement than of
deterioration.
68
Controls Patients
Trailmaking Test
pan A 41.3(16.1)
part B 62.6(24.1)
Stroop Test
word 40.6(5.1)
color 55.4(4.1)
color-word 93.7(17.7)
interference .58.3(12.0)
15 Word Test
total 49.0 (5.5)
delta 6.9(1.3)
delayed recall 10.3 (2.1)
recognition 29.4 (0.8)
session 1
(n = 14)
session 2
(n = 14)
session 3
(n = 14)
session 4
(n = 11)
session 5
(n = 5)
50.5 (23.3)
77.0 (26.4)
V i y .
50.4 (6.3)
63.0 (9.5)
134.1 (36.2)
71.1 (32.2)
45.2(16.6)
75.4 (30.4)
47.9 (8.4)
57.1 (9.2)
110.9(27.0)
53.8 (23.3)
41.3(14.6)
72.5(24.1)
49.8 (8.7)
63.3(13.4)
127.7 (40.1)
64.4 (30.9)
32.2(10.0)
78.8 (35.7)
47.4 (7.2)
64.4 (12.3)
138.4(50.9)
74 (39.2)
29.3 (5.3)
88.7 (57.5)
48.5 (8.4)
59.3 (7.0)
120.0(33.4)
61.0(31.0)
32.5 (9.3)
4.9(1.6)
6.4 (2.6)
27.0(2.1)
35.6 (11.6)
5.0 (2.2)
6.6 (2.6)
26.1 (2.8)
38.2 (8.6)
5.0(2.1)
7.6(2.5)
26.4 (3.5)
38.4(12.4)
4.2(1.5)
7.2 (3.6)
28.6 (2.6)
41 (15.6)
4.5 (3.0)
7.0 (3.7)
27.5(3.1)
1 able 2. Menu Results (standard deviations) of Neuropsychologic Tests of Matched Controls and Pa)icnts, During
Successive Test Sessions.
Statistical analysis {sample t-test) revealed significant differences between patients in session I versus matched controls (p
= < 0.001), but no significant inter-session differences (0.1 < p < 0.8); session 1 = pretherapeutic; session 2 = during che-
motherapy; session 3 = after chemotherapy; session 4 = 1 month after prophylactic cranial irradiation; session 5 = 5 months
after prophylactic cranial irradiation.
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Discussion
Follow-up assessments of cognitive func-
tion in patients with SCLC from diagno-
sis, or a comparison between their prethe-
rapeutic performance and that of matched
controls, have not been performed as yet.
The neurotoxicity of the combination of
chemotherapy and PCI, in the context of
SCLC, is described mainly as late
sequelae in long-term survivors.
Theoretically speaking, nonmetastatic
neurologic complications of SCLC or
sequelae of its treatment can arise at any
moment, starting from diagnosis.
Chemotherapy related cerebral injury pre-
sents itself early, within weeks to months
of treatment (14, 20). With the combina-
tion of cyclophosphamide, doxorubicin.
and etoposide as used in our study, howe-
ver, no CNS injury has been reported so
far. Laukkanen et al. (12) identified
headache and mild nausea during PCI,
and concentration difficulties and a non-
specific lack of energy from 1 month after
PCI as transient and early sequelae.
Licciardello et al. (16) described 2
patients with progressive confusion 6 and
10 weeks after PCI. Irreversible adverse
effects do occur usually 3 months after
PCI (14,20).
Pretherapeutic neuropsychologic test
results of the group of patients as a whole
were generally worse than those of the
matched controls. Possible explanations
could be that the patients were in sub-
optimal physical condition and were pre-
occupied with their future. The attending
effective changes may have influenced
their test performance. Akhough all
patients remained motivated and none
showed clinical evidence of significant
depression, their general physical and
mental condition cannot be ruled out.
Microscopic brain metastases and parane-
oplastic mechanisms may have further
compromised the results (5). Moreover,
we are unaware of the effects of chronic
cigarette smoking, prior medication or
brain traumas, and the interactions of
these interindividually different data with
the current treatment. Hill found that
smoking may have a negative effect on
performance speed in elderly adults (8).
An earlier study (21), performed by us,
revealed no focal deficits such as aphasia,
apraxia, or agnosia. None of the patients
showed clinical signs of these specific dis-
orders in the present study, although they
were not specifically tested for. The pre-
sent study also revealed no additional the-
rapy effects on measures of aspecific
effects of diffuse brain dysfunction;
during and after treatment, some neuro-
psychologic test results even improved
slightly. Standard neurologic examination
revealed no serious neurotoxicity; specific
history for cognitive dysfunction did not
reveal more than a slight indication of
brain dysfunction in some patients, objec-
tive CNS abnormalities were detected
only in patients with brain metastases.
This finding contrasts with several stu-
dies which have reported a considerable
number of severe neurologic complica-
tions of therapy, especially in long-term
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survivors (19,3,10,11.13,12,6,7,16). The
fraction dose of PCI in these studies
(3.10,11,13,12,6,7,16) was at least 3 Gy;
this may have been more harmful than
the 2 Gy used in our study.
The difference between the group of
patients in pretreatment condition and ;
the group of matched controls can not be
interpreted a priori as clinically signifi-
cant; although it could be meaningful for
the individual patient in view of the stan-
dard deviations. The same goes for the
therapy effects; although the mean group
results remained relatively stable, the
considerable standard deviations in com-
bination with the small sample size makes
it likely that the cognitive performance of
individual patients were impaired. The
number of patients is too small for defini-
te conclusions; half of the study popula-
tion developed brain metastases or died
before neurotoxicity assessment could be
performed, and we can not exclude long-
term effects. However, the differences
between patients in pretherapeutic con-
dition and matched controls may very well
have contributed to the short and long-
term neurotoxicity reported in other stu-
dies (19,3,10,11,13,12,6,7,21,16). Our
results confirm the importance of a pre-
therapeutic assessment in this field of
research.
Conclusions
In patients with SCLC who were treated
with chemotherapy and PCI, follow-up of
cognitive functioning revealed no adverse
treatment effects within 5 months after**
termination of PCI. However, when pre- '
therapeutically compared to matched con-
trols, patients performed significantly
worse, suggesting that a nontreatment
related cognitive impairment could exist
in patients with SCLC.
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Introduction
Central nervous system (CNS) metasta-
ses are an important cause of morbidity
and mortality in patients with small cell
lung cancer (SCLC) 11 ]. With lengthe-
ning survival the risk of CNS metastases
increases to a cumulative risk of 58-80%
in two-year survivors not treated with pro-
phylactic cranial irradiation (PCI) (2]. For
patients who did not achieve complete
remission (CR), the actuarial likelihood of
developing CNS metastases was nearly
100% at 2 years, irrespective of the admi-
nistration of PCI [.i]. PCI significantly
reduced the frequency of brain metasta-
ses in a number of prospective, randomi-
sed clinical trials [4|. Though there was
no evidence of improved survival, PCI
became an optional part of the treatment
program for patients with a CR to syste-
mic chemotherapy, with or without chest
radiation therapy [4].
It soon became evident, however, that the
application of PCI involved the risk of
serious CNS injury [5-9]. Both chemothe-
rapy and cranial irradiation are potentially
hazardous for the CNS and the white
matter in particular [10]. Small cell lung
cancer patients treated with chemothera-
py alone showed less adverse effects than
those who were treated with chemothera-
py and PCI |4 | . Administration of PCI in
larger fraction doses, concurrent with or
sandwiched by chemotherapy seemed to
be associated with a higher frequency of
CNS abnormalities |9 | . However, exact
frequency, severity, and etiology of these
CNS abnormalities in long-term survivors
of SCLC are unknown, at present.
Studies on neurotoxicity in SCLC lack
sufficient patient numbers and uniformity
to allow definite conclusions on this topic
[4,11-14].
Using neurologic and neuropsychologic
assessment, and computed tomography
(CT) scanning or magnetic resonance
(MR) imaging of the brain, the present
study describes the neurologic outcome of
59 long-term survivors, defined as
patients surviving the diagnosis of SCLC
tor more than two years. The purpose of
the current investigation was to isolate
residual effects of the treatment of
SCLC. It was hypothesised that the treat-
ment would affect mainly the cognitive
performance of the patients. An attempt
was made to asses the impact of different
treatment-protocols on learning and
memory, memory span, speed of informa-
tion processing, and attention shifting.
Specifically, the most sensitive neuropsy-
chologic tasks to detect deficits in these
cognitive domains were used to compare
patients not treated with PCI, patients
treated with PCI after chemotherapy,
patients treated with PCI concurrent
with or sandwiched by chemotherapy, and
matched controls.
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Patients and Methods
Patient population
Pulmonologists in the Netherlands were
asked to request patients surviving the
onset of SCLC more than two years to
take part in the present study on a volun-
tary basis. They were visited by the aut-
hors for neurologic (AvO) and neuropsy-
chologic assessment (BdG or RvV).
Within two months after these asses-
sments a CT or MR scan of the brain was
performed in the different hospitals.
Between January 1991 and January 1993,
59 patients were enrolled. Six patients
were excluded from further analysis; four
patients with a cerebrovascular accident,
one patient with a Korsakoff syndrome
due to alcohol abuse, and one patient
with a severe head injury prior to diagno-
sis of SCLC. For analysis of the neuropsy-
chologic test results and for the determi-
nation of treatment effects four more
patients were excluded, two because of
insufficient command of the Dutch langu-
age, and two patients because they were
not treated with chemotherapy or PCI.
Treatment
Fifty-one patients, were treated with che-
motherapy, with or without chest irradia-
tion. Thirty patients were treated with
PCI, 23 patients did not receive PCI.
Two patients were not treated with che-
motherapy or PCI. These latter two
patients underwent a lobectomy. in one
followed bv chest irradiation.
Patients were divided in three groups,
according to the received treatment:
group 1 chemotherapy alone (n = 21,
including two patients with insufficient
command of Dutch), group 2 PCI after
termination of chemotherapy (n = 19),
and group 3 PCI concurrent or sandwi-
ched with chemotherapy (n =11) .
Patient characteristics and treatment spe-
cifications are listed in
The group of controls comprised healthy
subjects (n = 29), enrolled in a study on
memory disturbances in the elderly [15].
They were matched on an individualised
basis to the patients for age and educa-
tional level.
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Patients ;,*
Characteristics ,,, ^ . , ; s .
survival
e d u c a t i o n l e v e l ' • *''' •'•.-!'' "*•'-
Chemotherapy
CTX,DOX,VCR
CTX,DOX,ETO
CTX,DOX,ETO/CTX,VCR,MTX
OTXA'CR.MTX
C:TX,CIS,ETO
CTX,CIS,ETO/CCNU,ETO,MTX
(rrX,CIS,ETO/CCNU,HMM
carhoplatin and ifosfamide
carboplatin and VCR
1 .ocoregional Radiotherapy
I'rophx lactic Cranial Irradiation
15 x J.O Civ
12x2.5Gy
H)x3.()Gy
group 1
n = 19
64.5 (7.2)
5.4 (2.8)
3.0(1.4)
, .•?
9
0
0
1
2
0
0
0
11
0
0
0
group 2
n = 19
59.7(9.1)
4.1 (2.5)
3.4(1.6)
1
16
0
0
0
0
1
1
0
9
3
10
6
group 3
n = 11
64.7 (9.9)
7.8(2.3)*
3.9(1.3)
0
1
7
1
0
0
1
0
1
9
1
5
5
Table 1. Patient characteristics and treatment specifications.
(iroup 1 =chemotherapy alone; group 2=seciuential prophylactic cranial irradiation; group 3=con-
current or sandwiched prophylactic cranial irradiation. Age, survival (*p=0.007. One Factor
Anova). and education level of patients are displayed as mean and (standard deviation). Matched
controls (n = 29) had a mean age 61.4 (7.2) year and education level of 3.5 (1.2). Different treat-
ment modalities are specified; CrTX=cyclofosfamide: DOX=doxorubicin: KTO=etoposide;
VCR=vincristine; ClS=cisplatin; MTX=methotrexate; HMM = hexamethylmelanine.
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Neurologic assessment
The neurologic evaluation included histo-
ry assessment of functional status, and
neurologic examination. We specifically
concentrated on complaints or abnormal
physical findings related to the CNS.
Patients were screened for intoxications,
head injuries, and cardiovascular risk fac-
tors as hypertension, diabetes mellitus,
and coronary artery disease. The use of
antihvpertensive or antidiabetic medica-
tions was used to define hypertension or
diabetes mellitus, respectively. The diag-
nosis of coronary artery disease required a
documented history of myocardial infarc-
tion or an abnormal electrocardiogram for
the presence of ischemic changes or
arrhvtmias. Functional status assessment
included a clinical rating scale for the abi-
lity to perform self care and basic social
maintenance using the Barthel score [16],
the Karnofsky scale [17], and the score ot
Order, Hellman and von Essen [18]-
Grading of ventricular enlargement,
cortical atrophy, cerebellar atrophy,
white matter lesions by G T and MR
scan
All CT and MR scans were reviewed by a
neuroradiologist (JW) who was unaware of
the treatment and clinical condition of
the patient. CT and MR scans were eva-
luated for ventricular enlargement, corti-
cal atrophy, comparison of cerebral and
cerebellar atrophy, and the extent of
white matter lesions. Ventricular enlarge-
ment was rated according to the Evans
index 119]. Cortical atrophy was judged as
none if no sulcus was wider than 5 milli-
metres, light if a few sulci were wider
than this value, moderate if more sulc.
but less than the half of them were wider
than 5 millimetres, and severe if more
than half of the sulci were wider than 5
millimetres. Visual assessment was used
for the comparison of cerebral and cere-
bellar atrophy as less, the same, or greater.
The extent of white matter lesions was
judged as none if no such lesions were
present, light if white matter lesions were
restricted to a periventricular zone of no
more than one ventricle width, moderate
if white matter lesions were scattered
throughout the white matter excepting
the capsula interna, and severe if the total
white matter was affected.
Neuropsychologic assessment
For the neuropsychologic testing battery
five tests (two memory tests and three
tests in which speed of performance was
the main parameter) were chosen because
of their sensitivity in distinguishing
between chronic solvent exposed workers,
intermittently exposed workers and heal-
thy controls [201: the Auditory Verbal
LearningTest(AVLT) 1211. the Digit
Span [21 ], a paper and pencil Memory
Scanning Test (MST) [22], Concept
Shifting Test (CST) [151, and the Stroop
Color-Word Test [21].
1) In the AVLT 15 one-syllable nouns,
recorded with a cassette tape, were pre-
sented five times in the same order. The
subjects were instructed to recall all
nouns thev could remember immediately
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after the presentation (immediate recall).
The measure parameters used in this test
are the number of words recalled on the
first trial, the sum of the differences
between the scores of the successive trials
(delta), the delayed recall and the delay-
ed recognition. The later two were meas-
ured 30 minutes after trial 5.
2) In the Digit Span Forwards the largest
number of digits of a sequence that was
repeated in the right order by the subject
was counted.
3) A paper and pencil MST tested the
slowing caused by memory load, in a fas-
hion similar to the Sternberg paradigm
[23|. The test consisted of four different
subtests, each on a separate sheet of A4
paper, containing a 12 x 12 matrix of let-
ters. In each matrix, 24 letters were target
letters and the other letters were distrac-
tcrs. For each subtest, the subject was
requested to memorize 1-4 letters, the
memory set, and to cross them out as
quickly as possible, without making
mistakes, each time they occurred on the
test sheet. In subtest 1, the memory set
consisted of 1 letter (all 24 target letters
were the same). In subtest 2, 3, and 4. the
memory set consisted of 2, 3, and 4 diffe-
rent target letters, respectively. The
intercept and the slope of the time scores,
calculated by means of linear regression,
are the parameters used with this test.
4) In Stroop Color-Word Test the sub-
ject's performance was measured as time
scores of the three subtests A, B, and C,
and the interference induced bv the
'Stroop' effect [21].
5) The CST consists of three subtests,
analogous to the Revised Trail Making
Test. Each subtest consists of 16 small
circles (diameter 15mm), grouped in a lar-
ger circle (diameter 16mm), printed on a
A4 paper. In the small circles the test
items are randomly printed in the small
circles: digits 1-16 in subtest A, letters A-
P in subtest B and both digits 1-8 plus
letters A-H in subtest C. The subjects are
requested to cross out the items in the
right order. The scores are time scores for
each of the three subtest and the effect of
interference induced by the digits/letters
category switch.
The different test parameters were com-
bined in four cognitive domains: learning
and memory, memory span, speed of
information processing, and attention
shifting. Both the interference effect of
the Stroop Test and the CST are viewed
as a measure of aspects of arousal and
alertness on executive functions [22], and
were combined in a relative score, accor-
ding the formula:
(C-A+B)/2)/(A+B)/2)*l(K), in which A,
B, and C represent the order of the three
sub tasks of the Stroop and the CST.
Statistical analysis
Univariate F-tests and Kruskal-Wallis test
were used to assess significance in the
distribution of characteristics, performan-
ce scores, and radiologic findings between
treatment groups. Differences in cogniti-
ve performance were assessed by univaria-
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e F-tests and MANOVA's. Pearson corre-
ations were used
Results
Neurologic assessment
None of the patients was institutionali-
sed Three patients received some
external domestic help. Of the 53 eligible
patients 47 lived with their partner and 6
lived alone. Except for intermittent use of
sleep medication, no psychoactive drugs
were used. Three patients used more
than four units alcohol on a regular daily
basis. Cardiovascular risk factors have
been recognised in 17 patients (32%); 9
patients group 1, 5 patients group 2. and 3
patients group 3 respectively.
All patients had optimal Barthel scores
and were able to perform basic self care.
Fifty percent of the patients had an opti-
mal Karnofskv score, the lowest score on
the Karnofskv scale was 60 (one patient in
group 3). The rating on the Karnofskv
scale was frequently more affected by the
pulmonary condition than their neurologic
condition. More than 50 percent of the
patients had an optimal rating on the
score of Order, Hellman, and von Essen
[181. Patients of group 1,2, and 3 did not
differ significantly with respect to their
functional status, as measured by the
Karnofskv score and the score of Order,
Hellman, and von Essen.
Neurologic assessment revealed no abnor-
malities in 32 (60%), impairment in 13
(25%), and slight disability in 8 (15%)
patients. Neurologic problems were seen
in 5 patients in group 1(24%), 8 patients
in group 2 (42%), and 8 patients in group
3 (73%), see *»Afr->. The two patients who
were not treated with chemotherapy or
PCI (age 74 and 80 years, and both with
cardiovascular risk factors) suffered
hearing loss but were otherwise neurologi-
cally normal. ...-•<{/
Features of mental impairment included
complaints of memory disturbances
(n=14), concentration problems (n = 3),
slight word findings problems (n = 2). and
calculation problems (n=l ) . Though
mental status and regular neurologic exa-
mination revealed no abnormalities, these
complaints had quite a great impact on
the social functioning of some patients;
i.e. an accountant resigned because of
memory and calculating problems, a busy
executive ended his career because his
inability to memorise agenda items, a
housewife felt uncomfortable not being
able to organise her domestic work as
before and noticed memory disturbances
and slight word finding problems when
she argued with other people.
Motor abnormalities included discrete
hemiparesis <n= 1), unstable gait or ataxia
(n = 5), pyramidal tract signs in the legs in
combination with incontinence of urine
(n = 2). The latter two patients were both
treated with chest irradiation. One
patient with memory disturbances develo-
ped visual complaints and an unstable
gait; she noticed distortions and discolora-
tion*. MR1 of her brain showed white
matter lesions right sided parieto-occipi-
tal and a mild cortical atrophy.
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Mental Complaints
memory disturbances
concentration disturbances
slight dysfasia
dyscalculia
Motor Abnormalities
discrete hemiparesis
unstable gait
pyramidal tract signs and
urine incontinence
Other
visual complaints
Total
symptomatic patients
asymptomatic patients
i-3'
14
3
2
1
1
5
21
32
Table 2. Results of neurologic assessment in 53 long-term small cell lung cancer survivors.
Ncuroradiologic assessment
Cranial CT scanning was performed in 20
patients (7 patients group 1, 8 patients
group 2, and 5 patients group 3) and MR
imaging in 21 patients (7 patients group
1, 9 patients group 2, 4 patients group 3,
and 1 patient not treated with chemothe-
rapy or PCI). CT and MR scans were eva-
luated for ventricular enlargement (Evans
index), cortical atrophy, comparison of
cerebral and cerebellar atrophy, and pre-
sence and extent of white matter lesions.
The Evans index was pathologic in one
patient only. The extent of cortical atro-
phy did not differ significantly between
groups (p = 0.3, Kruskal-Wallis test), see
/V/M" J. The atrophy of the cerebellum was
in proportion with the rest of the cere-
brum in most of the patients; judged as
less in three and as more in one patient
respectively. White matter lesions were
localised as primarily periventricular;
aspecific subcortical white matter lesions
were seen in only one patient. The predo-
minately periventricular localised white
matter lesions were significantly more
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Patients group 1
n = 14
group 2
n = 17
group 3
n = 9
Cortical Atrophy
none
mild
moderate/severe
White Matter Lesions
none
mild
moderate/severe
2(1/1)
9 (4/5)
3(2/1)
9 (5/4)
4 (1/3)
1 (1/0)
1 (0/1)
12 (5/7)
4(3/1)
6 (4/2)
8 (2/6)
3(2/1)
0 (0/0) -
4(3/1) V
5 (2/#)
1 d/0)
4(3/1)
4(1/3)
Table 3. Degree of cortical atrophy and white matter lesions.
Degree of cortical atrophy (p<0.3, Kruskal-W'allis test) and white matter lesions (p<().()2,
Kruskal-Wallis test) were established for different treatment groups; group 1 =treated with che-
motherapy alone; group 2 = treated with prophylactic cranial irradiation after termination of che-
motherapy; group 3 = treated with prophylactic cranial irradiation concurrent or sandwiched with
chemotherapy. Rersults are displayed as total numbers and specified for imaging technique num-
bers (CT/MR).
extensive in group 3 than in groups 1 and
2 (p = 0.02, Kruskal-Wallis test), see table
3. A cerebral MR scan made in one of the
two patients who were not treated with
chemotherapy or PCI showed mild white
matter lesions and moderate cortical atro-
phy.
Pearson correlations were studied
between the extent of white matter
lesions and type of brain imaging techni-
que, age, survival, presence of cardiovas-
cular risks factors, treatment group, num-
ber of chemotherapy courses, type of che-
motherapy, as well as fraction dose of
PCI. The Pearson correlation matrix
(r > 0.3, p < 0.05) showed a positive cor-
relation with treatment group 3 (0.423),
large number of chemotherapy courses
(0.301) and high fraction dose (0.300).
There was no significant correlation found
with the other factors.
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Patients
Learning and Memory
AVLT delta
AVLT delayed recall
AVLT delayed recognition
Memory Span
AVLT trial 1
MST slope score
Digit span
group 1
n = 19
4.05
6.68
13.05
4.31
13.29
4.83
Speed Information Processing
MST intercept score
CST subtest A
CST subtest B
Stroop subtest A
Stroop subtest B
Attention Shifting
Stroop interference effect
CST interferrence effect
51.61
53.63
62.88
63.00
76.00
111.08
28.79
group 2
n = 19
4.74
6.00
12.84
3.73
10.36
5.09
39.23
55.73
66.94
58.41
68.64
96.97
40.51
group 3
n = 11
3.45
5.18
12.81
3.27
12.20
5.60
36.51
55.11
53.11
60.50
69.30
194.06
40.57
controls
n = 29
6.10
10.14
14.10
5.50
9.80
5.20
34.66
29.17
32.82
44.20
57.36
93.57
63.52
p-values
F = 3.74
0.016
0.000
0.057
0.000
0.337
0.274
0.000
0.001
0.000
0.003
0.013
0.001
0.116
Table 4. Means of test parameters and p-values of univariate F-tests for different treatment groups
and matched controls.
(iroup 1 = treated with chemotherapy alone; group 2 = trcated with prophylactic cranial irradiation
after termination of chemotherapy; group 3=treated with prophylactic cranial irradiation concur-
rent or sandwiched with chemotherapy. Test parameters were combined in four cognitive domains;
\VLT= Auditory Verbal learning Test; MST= Memory Scanning Test; Stroop= Stroop Color-
Word Test; CST=Concept Shifting Test. High scores mean a good performance for the test para-
meters AVLT (delta, delayed recall, delayed recognition, and trial 1) and Digit span. Low scores
mean a good performance for the other parmeters.
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,europsychologic assessment Discussion
;eparate MANOVA's per cognitive
lomain indicated that the mean results of
Afferent patient groups of patients were
.ignif.cantiv worse than those of matched
controls, for each cognitive domairulcar-
ning and memory: W.Iks' Lambda -
0 634, F(9.175) = 4.005, p<-000; _
memo* span: W.Iks' Lambda = 0.68:,.
F(9 170) = 3.562, p < .000; speed of
information processing: W.Iks'Lambda-
0 600, F(15.174) = 2.289, p<-006; and
attention shifting: Wilks'Lambda-
0 735, F(6.140) = 3.555, p<-003 .
Comparisons of the three patient groups,
using MANOVA, however, did not show
differences within the four cognitive
domains.
The mean scores of the single test para-
meters and the p-values of univanate 1-
tests are given in table 4.1'nivanate K
tests revealed significant differences
between patients and controls tor most
test-parameters. No differences between
patients and controls were seen with
AVLT delaved recognition. Digit Span,
the slope score of the MST and the inter-
ference score of the CST.
To evaluate whether treatment variables
had an effect on individual cognitive per-
formances, Pearson correlations (r > 0.3,
p < 0 05) were calculated of test-parame-
ters and type of chemotherapy, number of
chemotherapy courses, fraction dose, and
total dose of PCI. None of these correla-
tions was signifieant above the 5% level.
Long-term survivors are relatively scarce
in neurotoxicity studies as a consequence
of the severe prognosis of SCLC From
the results of several neurotoxicity stu-
dies it becomes conceivable that PCI can
induce verv serious adverse reactions in
combination with chemotherapy in indivi-
dual SCLC patients 15-9, 13-14, 24-261.
Pedersen et al 141 concluded from the
combined data of 8 relatively small retro-
spective studies with a total of 123 long-
term sun'ivors of whom 102 received I Cl
that 45% had severe clinical CNS defect,
Clinical features of severe CNS injury
comprised repeatedly progressive cogniti-
ve failure and ataxic gait disturbances 13-
9 13 14 24-261. Radiologic findings indi-
cated loss ofbrain tissue 15-9. 13, 24-271,
especially of the periventricular white
matter [27-291.
In the present study, the long-term survi-
vors were in relatively good condition,
according to different rating scale score.
Ml patients were ambulatory and capable
of self care. In contrast to previous neuro-
.oxicitv studies 15-9, 13-14, 24-261, we
did not find seriously disabling CNS toxi-
citv in long-term survivors, although some
neurologic impairment was present.
Neurologic impairment was found more
frequently in more intensively treated
patients. Abnormalities concerned predo-
minate* complaints about their c c ^
functioning, with a considerable effect on
the social functioning of some patient,
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As the present study was retrospective, it
could be argued that patients with a seve-
re neurologic condition were not able to
visit the hospital and therefore could not
enter the study. On the other hand, 6
long-term survivors, patients on a regular
basis and suffering from severe to less dis-
abling CNS injury caused by cerebrovas-
cular accident (n=4), trauma (n=l ) , and
chronic alcoholism (n=l) participated in
the present study. Survival of these 6
patients varied from 3 to 11.5 (mean 6.5)
years.
The abnormalities seen on CT or MR
scan did not differ significantly for the
different patient groups, with the excep-
tion of the severity of white matter
lesions. The periventricular white matter
lesions have frequently been compared to
'leukoaraiosis' [33], which is commonly
seen in the elderly population and presu-
med to be caused by arteriosclerosis.
I .eukoaraiosis is correlated with age and
cardiovascular risk factors, hypertension in
particular 134-35]. Zimmerman et al. [36]
found that the radiation induced white
matter lesions had the same aspect on
MR scan as the white matter lesions seen
in the normal elderly population, which
makes the interpretation in our mainly
older patient population difficult.
I lowcvcr. no correlations were found with
age or cardiovascular risk factors in the
present study. The use of the same rating
scale for the extent of the white matter
lesions on CT scan and the for the detec-
tion of white matter lesions more sensiti-
ve MR technique [34-351, may have bia-
sed the results.
The white matter lesions are also compa-
red to the 'leukoencephalopathy' descri-
bed in children who were treated with
systemic chemotherapy and a CNS profy-
laxe [30-31]. Leukoencephalopathy is
thought to be the result of direct toxic
effects of irradiation or chemotherapy to
the neuroglia or indirect ischemic effects
to the neuroglia caused by a irradiation or
chemotherapy induced microangiopathy,
and to be progressive over time [32].
Many risk factors for the development of
neurotoxicity are combined in group 3:
PCI concurrent or sandwiched by chemo-
therapy, large number of chemotherapy
courses, higher fraction doses, and signifi-
cant longer survival. Consequently, our
CT and MR data do not allow definite
conclusions with regard to the white mat-
ter toxicity of PCI. The use of PCI con-
current or sandwiched by chemotherapy
has become obsolete at present.
Neuropsychologic assessment revealed no
significant differences between the three
groups of patients, whereas the cognitive
performance of all patient groups was sig-
nificantly worse when compared with the
control group. The type of treatment had
no effect on the cognitive impairment at
group or individual level. The results sug-
gest that the cognitive impairment of
SCLC patients is more disease related
than treatment related. We presumed
that emotional distress caused by the
knowledge of living with a malignant dise-
ase, and diminished physical condition
compromised the cognitive performance
of SCLC patients. The findings of the
present study are in line with results of a
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follow-up study of SCLC patients who
underwent serial neuropsychometric tes-
ting, before and after various treatments
1391.
As mean age and education level of
patients are similar in both studies, a
comparison of some results of the latter
study [39) with present results was valid.
It suggested that patients from the pre-
sent study have slower information pro-
cessing speeds. Speed of information pro-
cessing appeared to be a crucial parameter
of impairment in several neurologic as
well as psychiatric diseases. As the mean
survival of patients in the present study
was greater than in the follow-up study
[39], the lower information processing
speed may be caused by additional long-
term effects of SCLC or its treatment.
We cannot exclude that secondary anxiety
or mood disorders amplified the negative
impact of the disturbed emotional condi-
tion. Neither are we able to determine
the influence of progressive white matter
lesions, which may represent a late adver-
se effect of chemotherapy or cranial irra-
diation [10,27-32]. Laukkanen et al [26]
studied 12 long-term survivors, all treated
with PCI, and found their performance
limited by physical factors in three
patients, mild depression in three
patients, and significant emotional dis-
tress in two patients. Johnson et al [11],
who performed a follow-up study of 15
long-term survivors, found a slow progres-
sive decline in neuropsychologic function
to be correlated to the extent of cranial
CT or MR scan abnormalities.
The clinical finding that patients treated
with PCI (group 2 and 3) complained
more about their concentration and
memory than patients not treated with
PCI (group 1) was unsubstantiated by
statistic significance of the psychometric
results. The observation that the mean
scores on trial 1 of the AVLTof group 2
and 3 were lower than the score of group
1, may account for this apparent inconsis-
tency. Considering the first trial of the
AVLT as a word-memory span under
interference conditions, which are essen-
tial functions in everyday life, the group
differences between PCI treated and not
treated patients indicated a trend of
interference sensitivity difference and
may explain why the PCI groups complai-
ned more about their cognitive functions.
A similar finding was seen in a study com-
paring cognitive profiles of intermittently
solvent-exposed persons with healthy
control subjects [20|. The exposed sub-
jects who had strong complaints concer-
ning concentration and attention only had
lower scores on trial 1 of the AVLT.
Further clarification for the apparent
inconsistency between complaints and
psychometric results can be found in the
CST interference, which represents an
aspect of divided attention. According to
Stollery and Flindt [4()|. intermittently
solvent-exposed workers without memory
dysfunctions showed marked difficulties
when attention had to be divided over
two competing tasks. In concordance to
those findings, scores of the CST interfe-
rence showed a trend indicating that
groups 2 and 3 were slower than group 1,
in the present study.
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Our study differs from previous studies in
which CNS injury was heavily attributed
to PCI treatment. Though we do not
deny the potential hazardous possibilities
of PCI, we consider PCI to be one of the
factors capable of disturbing normal CNS
functioning. We conclude that the diagno-
sis SCLC yielded measurable neuropsy-
chologic effects compared to healthy sub-
jects; that more intensively treated
patients had relatively more neurologic
complaints especially with regard to their
cognitive functioning; that the significant
longer surviving patients of group 3, who
were treated with PCI concurrent or
sandwiched by chemotherapy, large num-
ber of chemotherapy courses, and higher
fraction doses, had more white matter
abnormalities; that there was no statistical
evidence for additional neurotoxicity of
treatment with PCI.
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9 General discussion
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This study deals with some clinical
aspects of brain metastases and its treat-
ment in small cell lung cancer. Brain
metastases are the most frequent neurolo-
gic complication of small cell lung cancer
(SCLC). In a longitudinal follow-up of
203 consecutive patients with SCLC,
brain metastases were found in 27
patients (13%) during the initial staging
procedure, and in 52 patients (21%)
during the course of the disease. The
cummulative risk of brain metastases
reached 47% for LD and 69% for ED
patients, at 2 years from diagnosis.
Paraneoplastic syndromes, which are fre-
quently associated with SCLC because of
its high neuroendocrine expression, have
a much lower occurance. The SIADH
(syndrome of inappropriate secretion of
antidiuretic hormone) was diagnosed in
11 patients (6.3%), antibody-medicated
paraneoplastic syndromes in 5 patients
(1.7%). The frequency of brain metasta-
ses was in accordance with data of pre-
vious studies; 10% (range, 0 to 16%) at
diagnosis of SCLC, 20% (range, 7 to 30%)
during therapy, and about 50% (range, 28
to 64%) at autopsy [1-2]. The frequency
of paraneoplastic syndromes may be unde-
restimated as only patients with a neuro-
logic presentation were diagnosed and our
attention was more or less fixed on central
nervous system (CNS) abnormalities.
Initial brain metastases responded signifi-
cantly better than delayed brain metasta-
ses to symptomatic treatment, in terms of
overall survival. Presently, symptomatic
treatment of brain metastases consists of
chemotherapy and/or radiotherapy. At
first, it was believed that the CNS was a
relative chemotherapy sanctuary as che- 5
motherapy increased survival but brain
metastases became more apparent. Later
on, it was recognised that cytotoxic drugs
can effectively penetrate into brain meta-
stases. Response rates of 75 % were repor-
ted for chemotherapy as well as radiothe-
rapy [4]. Brain metastases have, just as
the primary tumor, a high initial response
to therapy. In contrast the response of
brain metastases to chemotherapy and/or
radiotherapy following the first-line treat-
ment of the primary tumor, is much lower
and about 43 %. As symptomatic treat-
ment of brain metastases is always pallia-
tive and when possible, toxicity should be
kept to a minimum, it seems to make
sense to treat initial brain metastases pri-
marily with chemotherapy and delayed
brain metastases primarily with radiothe-
rapy. In case of initial brain metastases,
the response to first-line treatment
should be evaluated prior to using radio-
therapy. The value of consolidation radio-
therapy has yet to be thoroughly investi-
gated. In view of the shortened life
expectancy of patients with delayed brain
metastases, these patients should primari-
ly be treated with the slightly more effec-
tive and less toxic radiotherapy.
The histopathological subclassification
system for SCLC of the International
Association for the Study of Lung Cancer
(IASLC) is based upon cell culture work
and provided the best interobserver
reproductibility thusfar [5-7]. In this
study, subtyping was done of histologic as
90
well as cytologic material on which the
original SCLC diagnosis was made.
However, the frequences of the classic
(85%) and variant subtypes (together
15%) were in line with the results of pre-
vious studies [5,6,8]. The results of the
retrospectively done subtyping was corre-
lated to the results of the longitudinal fol-
low-up. Paraneoplastic syndromes were
found exclusively in patients with the
classic subtype. Statistically this finding
represented a trend and needs further
study. Nor were significant correlations
found between subtypes and metastatic
CNS pattern, developing brain metasta-
ses, or brain metastatic free survival. The
disproportionate distribution of subtypes,
and the possible presence of tumor hete-
rogeneity limited the predictive value of
the histopathologic subclassification of
the IASLC.
The early detection of brain metastases
can probably prevent sustained neurologic
impairment as the effect of treatment
seems to be primarily dependent on how
advanced the neurologic symptoms have
become when therapy is initiated [9]. In
contrast to the use of CT-scan (computed
tomography), MRI (magnetic resonance
imaging) yielded important additional
information to neurologic examination.
With the use of MRI it appeared possible
to detect brain metastases in neurologic
asymptomatic patients as contrast-enhan-
cing lesions. White matter lesions were
also very sensitively demonstrated by
MRI. Those focal or confluent, non con-
trast-enhancing hyperintensities on T2-
weighted images represented benign *MS
lesions in most of the patients. However,
in 2 of 4 neurologic symptomatic patients,
those lesions covered brain metastases
and part of them became contrast-enhan-
cing in follow-up MRI. Consequently, in
neurologic symptomatic patients with
deep white matter on perivcntricular
white matter hyperintensities on T2-
weighted images, follow-up MRI is
recommended as long as the usefulness of
a double dose of contrast is unknown.
Whether early detection of brain metasta-
ses yields a better response to therapy or
just shortens the silent period, is open for
discussion.
Delayed brain metastases can represent
seeding from a relapse of the primary
tumor, or represent secondary growth of
initial micro brain metastases.
Prophylactic cranial irradiation (PCM) was
introduced to prevent the secondary
growth of micro-metastases. In randomi-
zed studies, PCI proved to be effective in
disminishing the frequency of brain meta-
stases, from 25% to 6%, but failed to pro-
vide a consistent survival benefit [10].
Brain metastases were presumed to be a
sole CNS relapse in up to 10 % of
patients, while in the majority of patients
the appearance of brain metastases was
associated with a relapse of the primary
tumor. The efficacy of PCI was studied in
limited disease (LD) patients who achie-
ved complete remission (CR) only, becau-
se this category of patients could benefit
the most from PCI. Patients treated with
PCI had a slightly lower number of brain
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metastases, and a significantly longer
brain metastatic free and overall survival
than patients not treated with PCI.
These results should be ionterpreted with
caution. Only one patient, treated with
PCI, had a sole CNS relapse. In all other
patients, the appearance of brain metasta-
ses can reflect failure of PCI as well as fai-
lure of first-line treatment of the primary
tumor. PCI was applied non-randomized.
Patients treated with PCI had a longer
follow-up and received more frequent
loco-regional consolidation radiotherapy.
Finally, the number of patients was relati-
vely small. We concluded that because of
the small patient numbers and the many
biasing factors no conclusions should be
drawn.
Adverse effects of PCI are normally rela-
ted to as unexplained CNS abnormalities
in long-term survivors of SCLC.
Progressive anatomic changes are docu-
mented as white matter changes and
brain atrophy by CT-scanning and MRI.
Clinically, these anatomic abnormalities
are associated with a wide range of mani-
festations, varying from mild cognitive
deficits to rapid deteriorating dementia
syndromes |10-14|. Although it is extre-
mity difficult to attribute these changes
to the use of PCI, it is conceivable from
the abundant literature on this topic that
PCI potentially contributes to the deve-
lopment of CNS toxicity. Many toxifying
factors are involved in SCLC and its tre-
atment. SCLC, the disease itself, can
affect the cognitive performance by para-
neoplastic mechanisms or microcoscopic
brain metastases. Many of the drugs that
arc used during treatment of SCLC are
potentially neurotoxic, cytotoxic drugs in
particular. When cytotoxic drugs and PCI
are used together they can enhance each
others CNS toxicity. In SCLC, the use of
PCI concurrent or sandwiched by chemo-
therapy is associated with more and inten-
ser neurotoxicity [10-15].
Of the 18 long-term survivors in our longi-
tudinal follow-up study, the 9 treated
with PCI showed more possible treat-
ment related neurologic and radiologic
abnormalities than the remaining 9 not
treated with PCI. The possible treatment
related effects were relatively mild in
most of the patients, probably as a result
of treatment with PCI following comple-
tion of chemotherapy.
Neuropsvchometric follow-up of 32 SCLC
patients from diagnosis and during treat-
ment revealed no cognitive deterioration.
However, that group of patients scored
significantly less than the control group of
healthy subjects, who were matched age,
gender, and education level. It is possible
that the basic cognitive condition of
SCLC patients is already compromised at
diagnosis by psychologic factors and/or
paraneoplastic mechanisms. A poor basic
cognitive performance level may have be a
contibuting factor to the late neurotoxici-
ty. which is frequently associated solely to
PCI. The clinical implications of these
findings are diffficult to interpret as the
tests used are rather aspecific measures of
cognitive functioning and standard devia-
tions varied widelv.
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An analysis of a large group of long-term
survivors of SCLC revealed that the com-
bination of chemotherapy and PCI gene-
rated mild neurologic disability and
impairment only, in this group of patients
which were retrospectively studied.
Complaints of cognitive dysfunction were
heard more frequently from patients tre-
ated with PCI and the most of the
patients treated with PCI concurrent
with or sanwiched by chemotherapy. T h e
differences in neurologic cognitive impair-
ment were not substantiated by neuropsy-
chometric tests. Neuropsychologically, no
statistically significant difference were
found between the treatment groups. Nor
were correlations found betwen the indi-
vidual cognitive performance and factors
such as age, cardiovascular risk factors,
and different treatment modalities. T h e
apparent discrepancy between complaints
and neuropsychologic findings was partly
explained by a slightly worse score on trial
1 of the AVLT (auditors' verbal learning
task) and interference of the C S T (con-
cept shifting task). T h e trial 1 of the
AVLT represent a memory span under
interference conditions, which is an
essential function for every day use of
memory and concentration. T h e interfe-
rence of the C S T rewpresent an aspect of
divided attention, which is necessary to
perform two competing tasks in the same
time.
Compared to the results of patients who
were neuropsychologically tested at diag-
nosis and during treatment, long-term
survivors had a lower information proce-
sing speed. As mean age and education i^
level were similar in both studies the
validity of this comparison is justified, and
may be indicative of the long-term effects
of SCLC or its treatment. -as
In the group of patients treated with PCI
concurent with or sandwiched by chemo-
therapy, white matter lesions were more
common. I^euco-encephalopathy is recog-
nised as a late effect of the combination
of chemotherapy and PCI in children, tre-
ated for acute leukaemia. T h e survival of
the group of patients, treated with PCI
concurent with or sandwiched by chemo-
therapy, was significantly longer than of
the other groups. T h e longer survival may
account for the difference in white matter
lesions.
Another important observation was that
all patient groups scored significantly less
on the the different neuropsychologic
tests than a control group of healthy sub-
jects, who were matched for age, gender,
and education level. Again supporting evi-
dence was found for a disease rather than
a treatment effect in (INS toxicity. This
stresses the importance of a better under-
standing of the psychologic and copgniti-
ve functioning of cancer patients. Gross
disturbances are easily recognised but dis-
crete disturbances are hardly understood.
Nevertheless the fact that discrete cogni-
tive disturbances can have a great impact
on every day cognitive functioning. Our
limited understanding of the cognitive
functions impairs our ability to recognise
dysfunctions.
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Neurologic, neuropsychologic, psycholo-
gic, and radiologic study results have to be
linked for a more concise understanding
of cognitive functioning in cancer
patients, and of CNS toxicity in SCLC
patients in particular.
The clinician dealing with cancer patients
needs to be better equiped to distinguish
between normal and abnormal cognitive
functioning in order to detect neurotoxi-
city earlier. In individual patients, SCLC
and its tretment can generate serious side
effects. For a better understanding of the
CNS toxicity in SCLC we should not only
deal with those serious side effects but be
alert to the discrete CNS abnormalities
which are manifest in patients but not
immmediatly tied to the disease because
of their subtility. This holds especiaaly
true for SCLC] in which the majority of
patients already dealing with an extremity
bad prognosis lack the disposition to noti-
ce subtle dysfunction.
In general,the prognosis, in terms of over-
all survival and appearance of metastatic
neurologic complications, is mainly deter-
mined by the efficacy of the treatment of
the primary tumor. Treatment of the
peripheral neurologic complications is
predominately symptomatic. The poten-
tial benefits and risks of PCI have been
insufficiently researched. The small but
not insignificant cure rate in patients with
SCLC provide an incentive for further
study in the area of long term neurologic
complications.
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Small cell lung cancer (SCLC) is a relati-
vely common lung malignancy and gene-
rally has a bad prognosis. This cancer can
be accompanied by a wide range of neuro-
logic diseases, ranging from paraneoplastic
syndromes to brain metastases. This the-
sis focuses mainly on the brain metastases
related to SCLC.
Chapter 1 comprises a brief general intro-
duction and outlines this thesis' objecti-
ves.
Chapter 2 details the results of a longitu-
dinal neurologic follow-up of 203 consecu-
tive patients with SCLC]. The most recur-
ring neurologic complication was brain
metastasis. A total of 79 patients were
diagnosed as having brain metastases, of
these 27 had been diagnosed prior to any
treatment, and in the remaining 52 the
diagnosis was made either during or after
treatment of the lung carcinoma. The
cumulative risk of developing brain meta-
stasis was 47% in limited disease patients
and 69% for extensive disease patients.
Patients diagnosed with brain metastases
prior to SCLC treatment had a signifi-
cantly higher survival rate than patients
diagnosed with brain metastases in later
stages of the disease. Histopathologic exa-
mination of the brain metastases in 15
patients resulted in a different diagnosis
for 2 patients (13%); other primary tumor
n= 1, no SCLC after having achieved
complete remission for SCLC n= 1. The
discrepancy of the initial histologic diag-
nosis and that of the brain metastases
might be explained by tumor heterogenei-
ty, tumor changes influenced by treat-
ment or time, and the development of an
other primary tumor in the same patient.
The other neurologic complications of
SCLC are briefly described.
Using the guidelines provided by the
Pathology Panel of the International
Association for the Study of Lung Cancer
the predictive value of the histologic sub-
classification for neurologic complications
are discussed in chapter 3. A retrospective
revision was made of the material used to
establish the initial SCLC diagnosis of
the 239 patients participating in a longi-
tudinal neurologic follow-up study. The
subclassification of the histologic as well
as cytologic material of these patients
resulted in the following: classic cell type
n=178, variant cell type n=32 (mixed
cell type n = 31, combined cell type n= l ) ,
and non-classification n = 29 (only autopsy
material available n=14. initial diagnosis
altered n = 8, and slides missing n = 7).
The relationship between developing
brain metastases or the duration of brain
metastatic-free intervals and the histolo-
gic subtyping did not appear to be of any
statistical significance. Those patients
suffering neurologic complications of
paraneoplastic syndromes all had classic
small cell subtype. Not withstanding that
this result coincides with the result of the
experimental research where classic sub-
type was characterised by a greater mani-
festation of neuro-endocrine signs, this
finding merely represents a trend. Other
non-metastatic complications appeared
not so much related to the subtype, but
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more so dependant on treatment method
or coincidence. The conclusion being that
we find no clinical significance for histolo-
gic subclassification.
Chapter 4 and 5 continues with a discus-
.sion of the validity of using cranial compu-
ted- tomography (CT) scan and magnetic
resonance (MR) imaging in staging
patients with SCLC. As part of the initial
staging research 57 consecutive patients
underwent an examination by a neuro-
oncologist and a cranial CT scan. These
patients remained under the controlled
supervision of the neuro-oncologist
(during the first year quarterly, and bian-
nually there after). A cranial CT scan was
repeated if there was any suspicion of
brain metastases. Three patients were
excluded from the trial for various reasons
( cerebrovascular accident n = 2, leptome-
ningeal metastases n= l ) . Of the remai-
ning 54 patients, 50 were neurologically
asymptomatic and 4 were symptomatic.
In 3 patients the use of CT scan showed
aberrations symptomatic to brain metasta-
ses. The remaining patients showed no
signs of possible metastases.
The same trial was carried out in 40 con-
secutive patients but this time using MR
scan. Movement artefacts excluded 1
patient from this trial. Of the 11 patients
in which the MR scan showed deviations
similar to metastases 3 were neurologic
asymptomatic. The clinical staging of
these 3 patients did not change since they
already had extensive disease. Of the 14
patients with deep hyperintensive non-
Gadolinium enhanced white matter
lesions, 4 were neurologic symptomatic.
Two of these 4 developed brain metasta-
ses within 6 months. In the interim, part
of the deep hyperintensive non-
Gadolinium enhanced white matter
lesions became contrast enhanced. ••
We concluded that the CT scan is not
superior to neurologic examination for
detection of brain metastases in SCLC
patients. A MR scan, however, can contri-
bute significantly to the early detection of
brain metastases and contribute to the
primary staging procedure. Deep white
matter hyperintensities can make brain
metastases undetectable in neurologically
symptomatic patients.
Chapter 6 reports on the effectiveness
and safety of prophylactic cranial irradia-
tion (PCI) in a prospectively followed
group of 203 consecutive SCLC patients.
Of the 37 limited disease patients who
had achieved complete remission, brain
metastases developed in 3 of 17 treated
with PCI, versus 8 of 20 non-PCI treated
patients. The number of brain metastases
did not differ significantly. Patients who
underwent PCI treatment did have a con-
siderably longer brain metastatic-free
interval and survival rate. It should be
noted that this was a non-randomized
study, and that the remaining treatment
course of the SCLC was not totally equal,
as well as the fact that the patient popula-
tion was too small to show any signs of the
effects of PCI. Whether brain metastases
developed or not seemed largely depen-
dant on the behavior of the primary
tumor.
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The early as well as the later possible
adverse effects of the treatment are
covered in detail. Half of the 18 long-term
surviving patients had undergone PCI.
These patients had a marked increase in
cognitive function associated complaints.
There was also an increase in cranial CT
scan or MR abnormalities, all of which
maybe attributed to PCI treatment.
When taken in conjunction with existing
literature concerning the use and adverse
effects of PCI, it becomes plausible that
PCI treatment at least has a synergetic
effect on the potential neurotoxic treat-
ment of SCLC. The extent and severity
of toxicity to the central nervous system
as well as the effectiveness of PCI
remains unknown.
Cognitive functioning of SCLC patients
is the subject matter of chapter 7. In this
study 32 consecutive patients underwent
neuropsychologic testing, prior to, during,
and after treatment with chemotherapy
and/or PCI. During the same period these
patients were examined neurologically.
Patients with brain metastases were
excluded from the neuropsychologic fol-
low-up study. The pretreatment average
results were compared to those of a con-
trol group with similar age, sex, and intel-
ligence quotient. As a result of either
brain metastases or premature death only
14 patients participated in the second
trial session. 11 patients in the third and
fourth trial session, and 5 patients in the
last session. In patients with no indication
of brain metastases neurologic deviations
were not present. Less serious complaints
of concentration and memory, word fin-
ding problems, and libido deficiency were
indicated. When compared to the
matched control group, the patient group
clearly performed worse on the 15 Word
Auditory Verbal Learning task, the Stroop
color-word test and the Trailmaking test.
No further treatment-related negative
consequences were established.
We concluded that the disease itself can
negatively the patients cognitive functio-
ning abilities. Precluding a longitudinal
follow-up the effects of the disease and
those of the treatment are interchange-
able.
Chapter 8 presents the results of research
on 59 long-term SCLC survivors. Various
long treatment centres in the
Netherlands were approached and long-
term survivors were asked to voluntarily
take part in neurologic, neuropsychologic,
and neurologic testing. Since the primary
objective of the study was to determine
the neurotoxicity of the treatment 8
patients were not able to take part for
various reasons (cerebrovascular accidents
n=4, no chemotherapy or PCI treatment
n = 2. Korsakov syndrome n = l , severe
head trauma n= 1). The neurologic fin-
dings are described in 21 patients treated
solely with chemotherapy (group 1), 19
patients treated with PCI subsequent to
chemotherapy (group 2), and 11 patients
treated with concurrent or sandwiched
PCI and chemotherapy (group 3). A sta-
tistical comparison is made of the quanti-
fiable neuropsychologic and neuroradiolo-
gic data. The neuropsychologic test
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results were compared between the study
groups and also to the results of a healthy
group matched for age, gender, and edu-
cation level. Even though PCI treated
patients complained more of cognitive
dysfunction and though neurologic abnor-
malities were more often present in this
group of patients (in group 3 more than in
group 2), statistically these group diffe-
rences could not or at best only partially
be explained when neuropsychologic and
neuroradiologic data were compared.
Among the three patient groups there
were no neuropsychologic differences.
There was, however, a statistically signifi-
cant difference with the control group.
The statistics for the severity of cortical
atrophy and the presence of ventricular
enlargement and cerebellar atrophy
between the three groups was not repre-
sentative. Yet patients in group 3 did
show meaningful statistic differences
where white matter lesions are concerned.
Namely they had more white matter
lesions than the two other groups.
Patients in group 3 had a significantly lon-
ger survival rate. The three patients
groups did not differ in age, gender, edu-
cation level, cardiovascular risk factors or
research methods. The retrospective
study of these long-term SCLC survivors
concludes that no indications were found
for serious PCI related toxicity. The neu-
ropsychologic differences with the healthy
control group and the lack of significant
disparity among the three patient groups
may be indicative of the fact that the
patient groups were suffering from SCLC
and/or chemotherapy related effects.
The general discussion once again exami-
nes the results of all the studies and
draws the following conclusions:
• the most frequent neurologic complica-
tion of small cell lung cancer are brain '->
metastases. . . . . >, •;
• the course of the disease when comp-
ounded by brain metastases is related to
the point when the brain metastases are
diagnosed.
• histologic subclassification of the
International Association for the Study of
Lung Cancer is of no significance in pre-
dicting neurologic complications.
• in contrast to computed tomography
scanning, is magnetic resonance imaging
clearly superior to neurologic examination
in helping to establish an early diagnosis
of brain metastases.
• hyperintensive white matter lesions
impede the identification of brain meta-
stases in neurologic symptomatic-
patients.
• a longitudinal study is necessary to ade-
quately determine the neurotoxicity of
the treatment in small cell lung cancer.
• the overall diminished condition of the
patients, either due to the disease small
cell lung cancer itself or chemotherapy
must be taken into consideration when
explaining the cognitive dysfunction in
long-term survivors of small cell lung can-
cer
• retrospective study of 59 long-term sur-
vivors of small cell lung cancer could not
establish indications of frequent and seve-
re prophylactic cranial irradiation related
toxicity.
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• subtle cognitive impairment can have a
huge impact on daily life functioning in
long-term small cell lung cancer survivors.
• it is important to determine subtle
changes in cognitive functioning in order
to better understand and eventually pre-
vent central nervous system toxicity asso-
ciated with small cell lung cancer treat-
ment.
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Het kleincellig longcarcinoom is een rela-
tief veel voorkomende longmaligniteit
met een over het algemeen slechte prog-
nose. Een wijd spectrum van neurologi-
sche aandoeningen, varierend van parane-
oplastische syndromen tot hersenmetasta-
sen, kunnen de ziektc compliceren. Dit
proefschrift richt zich met name op de
hersenmetastasen van het kleincellig
longcarcinoom.
In hoofdstuk 1 worden, na een kortc alge-
mene inleiding, de doelstelingen van dit
proefstuk geformuleerd.
In hoofdstuk 2 worden de resultaten van
een longitudinale ncurologische follow-up
van 203 opeenvolgende patienten met
een kleincellig longcarcinoom beschreven.
I lersenmetastasen waren de meest fre-
c|uente ncurologische complicate van de
zickte. In het totaal werden bij 79 patien-
ten hersenmetastasen vastgesteld, in 27
patienten voor behandeling en in de res-
terende 52 patienten gedurende of na
behandeling van het longcarcinoom. Het
cummulaticve risico op het krijgen van
liersenmetastasen bedroeg 47% voor de
limited disease patienten en 69% voor de
extensive disease patienten. Na de diag-
nose van hersenmetastasen was de overle-
ving significant langer van patienten bij
wie de hersenmetastasen voor de behan-
deling van het kleincellig longcarcinoom
werden vastgesteld dan van de patienten
bij wie de hersenmetastasen pas later in
het verloop van de ziekte werden gedia-
gnostiseerd.
Histopathologisch onderzoek van de her-
senmetastasen van 15 patienten leverde
in 2 patienten (13%) een andere diagnose
op (andere primaire tumor n = l , niet-
kleincellig longcarcinoom nadat eerder
complete remissie was bereikt van een
kleincellig longcarcinoom n = l ) . Tumor
heterogeniteit, veranderingen in de tumor
onder invloed van behandeling of tijd en
de ontwikkeling van een andere primaire
tumor in dezelfde patient zouden de dis-
crepantie tussen de initiele histologische
diagnose en die van de hersenmetastasen
kunnen verklaren.
Kort worden de overige neurologische
complicacies van het kleincellig longcarci-
noom beschreven.
In hoofdstuk 3 wordt de voorspellende
waarde van het optreden van neurologi-
sche complicates besproken van de histo-
logische subclassificatie volgens de richt-
lijnen van het Pathology Panel van de
International Association for the Study of
Lung Cancer.
Met materiaal waarop de initiele diagnose
kleincellig longcarcinoom was gesteld van
de 239 opeenvolgende patienten, die
deelnamen aan een longitudinale neuro-
logische follow-up studie, werd retrospec-
tief gereviseerd. Dc subclassificatie van
zowel het histologische als het cytologi-
sche materiaal van deze patienten leverde
de volgende resultaten op: classic cell
type n=178, variant cell type
n = 32.(mixed cell type n = 31, combined
cell type n= 1) en geen classificatie n = 29
(alleen autopsie materiaal n = 14, initiele
diagnose veranderd n = 8 en coupes verd-
wenen n = 7). Het histologisch subtype
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bleek niet statistisch significant gerela-
teerd te zijn aan hct krijgen van hersen-
metastasen of de duur van hersenmetasta-
se-vrije interval.
Patienten met neurologische complicaties
van paraneoplastische syndromen bleken
alien het classic small cell subtype te heb-
bcn. Alhoewel deze bevinding aansluit bij
de resultaten van experimenteel onder-
zoek waarin het classic subtype zich
karakteriseerde door een hogere expressie
van neuro-endocriene kenmerken, repre-
senteerde deze bevinding statistisch
slechts een trend. Andere niet-metastati-
sche complicaties leken niet subtype
gerelateerd, doch eerder van de behande-
ling afhankclijk of op toeval berustend.
Concluderend vonden wij geen klinische
betekenis voor de histologische subclassi-
ficatie.
In hoofdstuk 4 en 5 wordt nader ingegaan
op de waarde van respectievelijk compu-
ted tomography (CT) scan en magnetic
resonance (MR) imaging van het cere-
brum voor de vroeg detectie van hersen
metastasen het stadieren van een patient
met een kleincellig longcarcinoom. Als
onderdeel van het initiele stadieringson-
derzoek ondergingen 57 opeenvolgende
patienten een onderzoek door een neuro-
oncoloog en een craniele CT scan. Deze
patienten bleven onder regelmatige con-
trole van de neuro-oncoloog(eerste jaar
elk kwartaal, daarna halfjaarlijks). Bij het
vermoeden van hersenmetastasen werd
de craniele CT scan herhaald. Drie
patienten werden van het onderzoek uit-
gesloten om diverse redenen (cerebrovas-
culair accident n=2, leptomeningeale
metastasen n = l ) . Neurologisch waren 50
van de overige 54 patienten asymptoma-
tisch en 4 symptomatisch. CT scan lever-
de bij hersenmetastasen passende afwij-
kingen op in 3 patienten. In de overige '
patienten werden geen mogelijk op meta-
stasen berustende afwijkingen gevonden.
Met MR scan werd hetzelfde onderzoek
herhaald in 40 andere opeenvolgende
patienten. Een patient werd wegens
bewegingsartefacten uitgesloten van het
onderzoek. Van de 11 patienten met op
metastasen lijkende afwijkingen op MR
scan waren 3 patienten neurologisch
asymptomatisch. De klinische stadiering
van deze drie patienten veranderde niet
omdat zij reeds een extensive disease
hadden. Van de 14 patienten met diep in
de witte stof gelegen, hyperintense, niet
met Gadolineum aankleurende laesies
waren 4 patienten neurologisch sympto-
matisch. Twee van deze 4 patienten kre-
gen binnen 6 maanden hersenmetastasen.
Ken deel van de aanvankelijk niet aan-
kleurende laesies bleek inmiddels veran-
derd te zijn in aankleurende laesies. Wij
concluderen dat CT scan geen meerwaar-
de heeft boven het neurologisch onder-
zoek voor de detectie van hersenmetasta-
sen bij patienten met een kleincellig
longcarcinoom en derhalve van belang kan
zijn voor het initiele stadierings onder-
zoek. MR scan daarentegen kan wel dege-
lijk bijdragen aan de vroegdiagnostick van
hersenmetastasen. Dat de diepgelegen,
hyperintense, niet met Gadolineum aan-
kleurende witte stof laesies in neurolo-
gisch symptomatische patienten hersen-
metastesen kunnen maskeren.
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In hoofdstuk 6 wordt verslag gedaan van
de effectiviteit en de veiligheid van pro-
fylactische schedel bestraling (PCI) in
een groep van 203 opeenvolgende patien-
ten met een kleineellig longcarcinoom,
die prospectief werden vervolgd. Van de
37 limited disease patienten, die een
complete remissie bereikten, kregen 3
van de 17 met PCI behandelde patienten
hersenmetastasen versus 8 van de 20 niet
met PCI behandelde patienten. Het aan-
tal hersenmetastasen verschilde niet sta-
tistisch significant. De met PCI behan-
delde patienten hadden echterwel een
significant langer hersenmetastase-vrij
interval en een significant langere overall
overleving. Hierbij moet worden aangcte-
kend dat het een niet-gerandomiseerde
studie betrof, de overige behandeling van
het kleineellig longcarcinoom niet voile-
dig gelijk was en dat de patientengroepen
te klein zijn voor het aantonen van een
PCI effect. I let wel of niet optreden van
hersenmetastasen leek vooral bepaald
door het gedrag van de primaire tumor.
De vroeg en laat optredende mogelijke
bijwerkingen van de behandeling worden
in detail besehrcven. Van de 18 langdurig
overlevende patienten waren 9 met PCI
behandeld. Mogelijk als gevolg van deze
bestraling, presenteerden de met PCI
behandelde patienten beduidend mecr
klachten aangaande hun cognitief functio-
neren en hadden zij vaker een afwijkende
craniele CT of MR-scan.
Tesamen met gegevens uit de literatuur
lijkt het aannemelijk dat PCI op zijn
minst een synergistisch effect kan hebben
op de potentieel neurotoxische behande-
ling van het kleineellig longcarcinoom. De
exacte ernst en frequentie van de centraal
zenuwstelsel toxiciteit zijn echter onbe-
kend, evenals de effectiviteit van PCI.
Het cognitieve functioneren van patien-
ten met een kleineellig longcarcinoom is
het onderwerp van studie in hoofdstuk 7.
Voor deze studie werden 32 opeenvolgen-
de patienten neuropsychologisch onder-
zocht, voor, gedurende en na behandeling
met chemotherapie en profylactische
schedel bestraling (PCI). In dezelfde
periode werden patienten ook neurolo-
gisch onderzocht. Patienten met hersen-
metastasen werden van de neuropsycholo-
gische follow-up studie uitgesloten. Van
de patienten groep werden de gemiddel-
de resultaten voor behandeling vergele-
ken met die van een voor leeftijd,
geslacht en intelligence quotient
gematchte controle groep gezonde vrijwil-
ligers. Door hersenmetastasen of vroegtij-
dig overlijden waren voor de tweede
onderzoeks sessie 14, voor de derde en
vierde onderzoeks sessie 11 en voor de
vijfde onderzoeks sessie 5 patienten
beschikbaar. Neurologisch werden geen
afw ijkingen gevonden in patienten zonder
aanwijzingen voor hersenmetastasen.
Zowel voor als tijdens behandeling wer-
den lichee klachten over concentratie-,
geheugen-, woordvindings- en libido
stoornissen geuit. Gemeten met de 15-
woorden test, de Stroop test en de
Trailmaking test presteerden de patien-
ten voor behandeling significant slechter
dan de gematchte controle groep. Er wer-
den geen additionele negatieve effecten
van de behandeling op het cognitieve
functioneren vastgesteld.
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Wij concludeerden dat het cognitieve
functioneren van patienten ook door de
ziekte zelf negatief kan worden bein-
vloed. Zonder longitudinale follow-up
kunnen de effecten van de ziekte met die
van de behandeling verwisseld worden.
In hoofdstuk 8 worden de resultaten
weergegeven van een onderzoek naar de
centraal zenuwstelsel afvvijkingen bij 59
langdurig overlevende patienten met een
kleincellig longcarcinoom. In diverse long-
centra in Nederland werden langdurig
overlevende patienten gevraagd om zich
op vrijwillige basis neurologisch, neuro-
psychologisch en neuroradiologisch tc
laten onderzoeken. Omdat de studio pri-
mair was ontworpen om de neurotoxiciteit
van de behandeling van het kleincellig
longcarcinoom vast te stellen, werden 8
patienten van het onderzoek uitgesloten
om diverse rcdencn (cerebrovasculair
accident n = 4, geen behandeling met che-
motherapie of PCI n = 2, Korsakov syn-
droom n= I, ernstig schedeltrauma n = l).
De neurologische bevindingen worden
beschreven bij 21 alleen met chemothera-
pie behandelde patienten (groep 1), 19
met PCI na beeindiging van de chemo-
therapie behandelde patienten (groep 2)
en 11 gelijktijdigof gesandvviched met
PCI en chemotherapie behandelde
patienten (groep 3). De gekwantificeerde
neuropsychologischc en neuroradiologi-
sche data worden statistisch vergeleken.
De neuropsychologische testresultaten
worden zowel onderling als met die van
een groep voor leeftijd, geslacht en oplei-
dingsniveau gematchte controlegroep
gezonde personen vergeleken.
Alhoewel met PCI behandelde patienten
meer klaagden over cognitief dysfunktio-
neren en bij hen meer neurologische
afwijkingen werden geconstateerd (in
groep 3 meer dan in groep 2), konden
deze groepsverschillen niet of slechts
gedeeltelijk statistisch worden bevestigd
bij de vergelijking van de neuropsycholo-
gische en neuroradiologische data.
Neuropsychologisch verschilden de
patientengroepen onderling niet. Wei ver-
schilden alle patientengroepen statistisch
significant met de controle groep. De
mate van corticale atrofie en het voorko-
men van ventrikelverwijding en cerebel-
laire atrofie verschilden statistisch niet
significant tussen de drie groepen patien-
ten. Wei vertoonden patienten van groep
3 statistisch significant meer witte stof
laesies dan de andere twee patientengroe-
pen. Patienten van groep 3 hadden een
significant langere overlevingsduur. De
patientengroepen verschilden niet qua
leeftijd, geslacht, opleidingsniveau, car-
diovasculaire risicofaktoren of gebruikte
onderzoekstechnieken.
Wij concludeerden dat in het retrospec-
tieve onderzoek van deze langdurig over-
levende patienten met een kleincellig
longcarcinoom geen aanwijzingen werden
gevonden voor het frequent voorkomcn
van een ernstige PCI gerelateerdc toxici-
teit. Het ontbreken van duidelijke
groepsverschillen en het significante ver-
schil met de controlegroep neuropsycho-
logisch, doet eerder een ziekte- en/of che-
motherapie effect vermoeden.
In de algemene discussie wordt nog eens
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In de algemene discussie wordt nog eens
ingegaan op de resultaten van alle onder-
zoeken en worden de volgende conclusies
getrokken:
• hcrscnmetastasen zijn de meest fre-
c|ucntc neurologische complicatie van het
kleincellig longcarcinoom.
• het beloop van de door hersenmetasta-
sen gecomplicecrde ziekten is mede
afhankelijk van het tijdstip waarop de her-
senmetastasen worden gediagnosticeerd.
• voor het voorspellen van neurologische
complicaties heeft de histologische sub-
classificatie van de International
Association for the Study of Lung Cancer
geen betekenis.
• voor de vroegdiagnostiek van hersenme-
tastasen heeft magnetic resonance ima-
ging in tegcnstelling tot computer tomo-
graphy een meerwaarde boven neurolo-
gisch onderzoek.
• in neurologisch symptomatische patien-
ten vormen de diep gelegen hyperintense
witte stof laesies een beletsel voor de
vroegdetectie van hersenmetastasen.
• voor het adequaat vaststellen van de
ncurotoxicitcit van de behandeling van
het kleincellig longcarcinoom is een longi-
tudinale studie noodzakelijk.
• bij de verklaring van de cognitieve pro-
blemen, die kunnen worden aangetroffem
bij langdurig overlevendc patienten, moet
rekening worden gehouden met een door
de /.iekte en chemotherapie verminderde
algehele conditie van de patient.
• retrospectief onderzoek van 59 langdu-
rig overlevende patienten met een klein-
cellig longcarcinoom bracht geen aanwij-
zingen voor het bestaan van emstige aan
profylactische schedelbestraling gerela- •••
teerde toxiciteit.
• subtiele cognitieve problemen kunnen
een grate impact hebben op het dagelijks
funktioneren van langdurig overlevende
patienten met een kleincellig longcarci-
noom.
• voor een beter begrip en eventuele pre-
ventie van de centraal zenuwstelsel toxi-
citeit van de behandeling van het klein-
cellig longcarcinoom is het van belang om
een achteruitgang in het cognitieve funk-
tioneren vroeg vast te stellen.
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